Document:

<PAGE>

                                                                    EXHIBIT 10.3

                             GENOMICA CORPORATION
                              FOUNDERS AGREEMENT

     THIS AGREEMENT is made as of the   22  th day of March, 1996, by and among
Genomica Corporation, a Delaware corporation, (the "Corporation"), Steven Cozza
("Founder") and the persons (the "Purchasers") named in Schedule I to a certain
Series A Convertible Preferred Stock Purchase Agreement of the Corporation dated
the date hereof (the "Purchase Agreement").

                                    RECITALS
                                    --------

     The Corporation is engaged in the highly competitive business of
researching, developing, manufacturing and marketing computer software for the
biotechnology industry on an international basis.  Founder and the Corporation
recognize and affirm that success or failure in this highly technical and highly
competitive business is dependent on the ability of the Corporation to (1)
develop and protect proprietary technology which will give the Corporation a
competitive advantage in the marketplace; (2) incorporate this technology into
products which themselves will or may become proprietary; and (3) develop and
utilize processes which may be proprietary to accomplish (1) and (2) above.

     In order to achieve the above objectives, the Corporation has expended and
will continue to expend substantial time, effort and financial resources.  These
activities include research, the attraction and training of key employees, and
establishing relationships with necessary resources outside the Corporation.  If
information regarding the Corporation's research, processes or products were to
fall into the hands of a competitor of the Corporation, it could be used in a
manner which would cause serious and irreparable financial and business damage
to the Corporation.  For this reason, all information related to the
Corporation's technology, research, products, and business strategies is
considered to be confidential information which is proprietary to the
Corporation.

     In addition, the Purchasers intend to invest in the Corporation pursuant to
the Purchase Agreement based on the foregoing assumptions and such investment is
contingent upon the execution and delivery of this Agreement by the Corporation
and Founder.

                                   AGREEMENT
                                   ---------

     NOW, THEREFORE, in consideration of the above representations and
understandings, and the promises and mutual agreements set forth below, the
parties agree, effective on the date of the Agreement, to the following terms
and conditions:
<PAGE>

     1.  Services.  Founder agrees to serve the Corporation as reasonably
directed by its Board of Directors or its designee, consistent with the scope of
expertise and other employment obligations of Founder.  Such services may
include participation in the Corporation as a director, officer, scientific
advisor, consultant, contractor and/or, with the agreement of Founder, an
employee. In all such cases, the terms and conditions of this Agreement will
continue to be binding.

     2.  Founder's Stock.  Founder has purchased from the Corporation an
aggregate of 30,000 shares of Common Stock (the "Shares") at a per-share
purchase price of $.001 (the "Original Purchase Price") as more specifically set
forth on Schedule 1 hereto.  Founder's Shares shall be subject to a number of
restrictions as set forth in this Agreement.  Certain of the restrictions with
respect to Founder's Shares may terminate under various conditions pursuant
hereto in consideration for Founder's service to the Corporation as described
herein.

     3.  [INTENTIONALLY OMITTED]

     4.  Disclosure and Assignment of Technology to Corporation.  Concurrently
with the execution of this Agreement, Founder is executing and delivering a
Nondisclosure Agreement substantially in the form set forth as Exhibit A hereto
(the "Nondisclosure Agreement").

     5.  [INTENTIONALLY OMITTED]

     6.  Remedies in the Event of Breach.  The Corporation, the Purchasers and
Founder understand and agree that any breach or threatened breach by the
Corporation or Founder of any of the provisions hereof cannot be remedied solely
by the recovery of damages, and in the event of any such breach or threatened
breach, the Corporation or the Purchasers, as the case may be, shall be entitled
to injunctive relief, restraining Founder, and any business, firm, corporation,
individual or other entity participating in such breach or attempted breach from
engaging in any activity which would constitute a breach.  The Corporation, the
Purchasers and Founder further agree that any dispute arising under the terms of
this Agreement shall be decided in accordance with the rules then in effect of
the American Arbitration Association, and any arbitration award may be entered
in a court of competent jurisdiction and enforced as a judgment thereof.
Nothing herein, however, shall be construed as (i) prohibiting the Corporation,
the Purchasers or Founder from pursuing, in conjunction with an injunction or
otherwise, any other remedies available in equity or at law for any such breach
or threatened breach, including the recovery of damages; or (ii) limiting the
Corporation's remedy against Founder as set forth in Section 13 below.

     7.  Transferability.  The Corporation and Founder agree (i) that Unvested
Shares (as defined below) may not be sold, pledged or otherwise transferred
("Transferred") without the consent of the Board of Directors in its sole
discretion

                                       2
<PAGE>

(except pursuant to Section 9 below); and (ii) Vested Shares (as defined below)
may be Transferred only in accordance with the provisions set forth herein and
only if the transferee of such Vested Shares agrees in writing to be bound by
the provisions of Sections 9, 10, 11, 13 and 14 hereof. Any Founder's Shares
Transferred not in accordance with the preceding sentence shall be void, ab
initio.

     8.  Founder's Stock.  Founder's Shares shall be affected as follows:

     (A) In the event (i) Founder dies; (ii) of a breach by Founder of any of
the terms of the Consulting Agreement or the Common Stock Acquisition Agreement
by which Founder purchased the Founder's Shares; or (iii) the Consulting
Agreement shall have been terminated by the Corporation for Due Cause (as such
term is defined in the Consulting Agreement) or if Dr. Marr voluntarily
terminates the Consulting Agreement (any such case, a "Discontinuation Event"),
certain of Founder's Shares, defined below as "Unvested Shares," shall be
repurchased and paid for in full by the Corporation at the Original Purchase
Price within 30 days of such Discontinuation Event.  Unvested Shares shall be
those Founder's Shares which have not yet vested according to the schedule set
forth in Schedule 1 hereto.  Notwithstanding the preceding sentence, in the
event the Corporation's Board of Directors approves a sale or merger (other than
a merger with or into a wholly-owned subsidiary of the Corporation or a merger
in which the Corporation is the surviving entity) of the Corporation or an
initial public offering of the Corporation's stock (any of which events is
defined herein as a "Triggering Transaction"), Founder will be notified of such
Board action.  Any of Founder's then Unvested Shares will become Vested Shares
(as defined below) simultaneously with the consummation of the Triggering
Transaction.  Upon the occurrence of a Discontinuation Event, all of Founder's
Unvested Shares shall forever remain Unvested Shares.

     (B) Upon the occurrence of a Discontinuation Event, Founder's Shares which
are vested pursuant to Schedule 1 hereto ("Vested Shares") may be repurchased by
the Corporation, solely at the option of the Corporation (the "Corporation
Option"), at Fair Market Value (as defined below).  The Corporation agrees to
give Founder (or his estate) notice of its intent to exercise the Corporation
Option within ninety (90) days of the date of such Discontinuation Event and to
pay for those shares for which it exercises such Corporation Option as follows:
3/24ths of the total price within 90 days of the date of the Discontinuation
Event, with the balance to be paid in equal monthly installments over the next
succeeding twenty-one months.

     (C) Termination For Cause.  Prior to the Corporation's initial public
offering, in the event of a Discontinuation Event with respect to Founder
occurring as a result of an event set forth in clauses (ii) or (iii) of Section
8(A) above, then with respect to any of Founder's Shares not repurchased by the
Corporation pursuant to Sections 8(A) or 8(B) above, Founder shall, in all
matters put forth to a vote of the holders of Common Stock (i) cause such
Founder's Shares to be represented at any meeting of the stockholders of

                                       3
<PAGE>

the Corporation and (ii) vote such shares in the same proportion and in the same
manner as all other Common Stock is voted.

     (D) Fair Market Value.  For the purposes of Section 8(B), Fair Market Value
shall be that value as determined in good faith by the Board of Directors.  Any
Founder (or his estate) may request an appraisal by written notice of objection
delivered not later than fifteen (15) days after receipt of such Fair Market
Value determination by the Board of Directors.  If an appraisal is demanded, the
Corporation shall select an appraiser reasonably acceptable to Founder (or his
estate) to appraise Founder's Vested Shares, and the repurchase price payable
upon the Corporation's exercise of the Corporation Option shall be the higher of
such appraisal and such Fair Market Value determination by the Board of
Directors.  If such appraisal results in a valuation more than 10% higher than
the Fair Market Value determination by the Board of Directors, then all expenses
of such appraisal shall be paid by the Corporation; otherwise, all expenses of
such appraisal shall be paid by Founder (or his estate).

     9.  Approved Sale of Corporation.  (A) If the Corporation's Board of
Directors has adopted a resolution of the Board of Directors approving the sale
of the Corporation to any person (such person, the "Acquiring Entity"), whether
by merger, consolidation, sale of all or substantially all of the Corporation's
assets or sale of all of the outstanding capital stock (such sale, an "Approved
Sale"), Founder and each Purchaser will consent to, vote for and raise no
objections against the Approved Sale, and if the Approved Sale is structured as
a sale of stock, Founder and each Purchaser hereby agrees to sell all of their
respective Shares (and all rights thereto) on the terms and conditions approved
by the Board of Directors, provided that each holder of Common Stock receives in
the Approved Sale the same amount and type of consideration for its interest in
the Corporation as is received by the holders of the Series A Convertible
Preferred Stock, (the "Preferred Stock"), assuming such holders had converted
their respective shares of Preferred Stock into Common Stock. Founder and each
Purchaser will take all actions reasonably required to facilitate and consummate
an Approved Sale of the Corporation.

     (B) The Corporation shall give written notice (a "Sale Notice") of any such
Approved Sale to Founder and Purchasers.  A Sale Notice shall contain  (i) the
name and address of the prospective Acquiring Entity; (ii) the purchase price
and other material terms and conditions of the Approved Sale; (iii) the date on
which the Approved Sale is intended to be consummated; (iv) the date on which
the Corporation's Board of Directors approved the Approved Sale and (v) the
Founder's and Purchaser's Shares proposed to be sold.  Upon receipt of a Sale
Notice, Founder and each Purchaser shall be required to consent to such Approved
Sale and to sell its Founder's or Purchaser's Shares, as the case may be, to the
Acquiring Entity designated therein within 30 days of receipt thereof or such
later date as may be specified in the Sale Notice.  No Purchaser or Founder
shall be required to make any representations and warranties other than
representations and warranties concerning its ownership of such Founder's or
Purchaser's Shares, the absence

                                       4
<PAGE>

of any liens or encumbrances thereon and its authority to sell such Shares; and
provided further that, if the terms of such Approved Sale provide for the escrow
of any amount of proceeds resulting from an Approved Sale or to accept
indebtedness or other securities subject to indemnification or other rights of
offset, then Founder and Purchasers shall be required to escrow a pro rata
amount of its proceeds from such Approved Sale and/or to accept such
indebtedness or other securities.

     (C) If the Corporation or Founder, in connection with any Approved Sale,
enters into any negotiation or transaction for which Rule 506 (or any similar
rule then in effect) promulgated by the Securities and Exchange Commission under
the Securities Act may be available with respect to such negotiation or
transaction (including a merger, consolidation or other reorganization), Founder
will at the request of the Corporation, appoint a purchaser representative (as
such term is defined in Rule 501(h) promulgated by the Securities and Exchange
Commission under the Securities Act) reasonably acceptable to the Corporation.
If Founder appoints the purchaser representative designated by the Corporation,
the Corporation will pay the fees of such purchaser representative, but if
Founder declines to appoint the purchaser representative designated by the
Corporation, Founder will appoint another purchaser representative (reasonably
acceptable to the Corporation), and Founder will be responsible for the fees of
the purchaser representative so appointed.

     10.  Right of First Refusal.  (A) Except pursuant to Section 9 above, if at
any time Founder desires to sell for cash all or any part of Founder's Shares
pursuant to a bona fide offer from a third party (the "Proposed Transferee"),
Founder shall submit a written offer (the "Offer") to sell Founder's Shares (the
"Offered Shares") to the Purchasers on terms and conditions, including price,
not less favorable to the Purchasers than those on which Founder proposes to
sell such Offered Shares to the Proposed Transferee.  The Offer shall disclose
the identity of the Proposed Transferee, the Offered Shares proposed to be sold,
the total number of Founder's Shares owned by Founder, the terms and conditions,
including price, of the proposed sale, that the proposed buyer has been informed
of the rights and obligations provided for in this Section 10 and Section 11
below and has agreed to purchase Offered Shares in accordance with the terms of
this Agreement, and any other material facts relating to the proposed sale.  The
Offer shall further state that the Purchasers may acquire, in accordance with
the provisions of this Agreement, all but not less than all of the Offered
Shares for the price and upon the other terms and conditions, including deferred
payment (if applicable), set forth therein.

     (B) Each Purchaser shall have the absolute right to purchase that number of
Offered Shares as shall be equal to the number of Offered Shares multiplied by a
fraction, the numerator of which shall be the number of Purchasers' Shares (as
defined below) then owned by such Purchaser and the denominator of which shall
be the aggregate number of Purchasers' Shares then owned by all of the
Purchasers.  For purposes of this Section 10, all of the securities of the
Corporation which a Purchaser has acquired, or has

                                       5
<PAGE>

the right to acquire from the Corporation, upon the conversion, exercise or
exchange of any of the securities of the Corporation then owned by such
Purchaser shall be deemed to be Purchasers' Shares then owned by such Purchaser.
(The amount of Offered Shares that each Purchaser is entitled to purchase under
this Section 10(B) shall be referred to as its "Pro Rata Fraction").

     (C) The Purchasers shall have a right of oversubscription such that if any
Purchaser fails to accept the Offer as to its Pro Rata Fraction, the other
Purchasers shall, among them, have the right to purchase up to the balance of
the Offered Shares not so purchased.  Such right of oversubscription may be
exercised by a Purchaser by accepting the Offer as to more than its Pro Rata
Fraction.  If, as a result thereof, such oversubscriptions exceed the total
number of Offered Shares available in respect of such oversubscription
privilege, the oversubscribing Purchasers shall be cut back with respect to
their oversubscriptions on a pro rata basis in accordance with their respective
Pro Rata Fractions or as they may otherwise agree among themselves.  In the
event that the Purchasers in the aggregate shall not have elected in the manner
set forth below to purchase all of the Offered Shares, the Purchasers shall not
have the right to purchase any of the Offered Shares and the Founder shall have
the right to sell the Offered Shares in accordance with Section 10(E) below.

     (D) If the Purchasers, in the aggregate, desire to purchase all of the
Offered Shares, such Purchaser(s) shall communicate in writing their election to
purchase to Founder, which communication shall state the number of Offered
Shares each Purchaser desires to purchase (which shall in the aggregate be equal
to all the Offered Shares) and shall be given to Founder within thirty days of
the date the Offer was made.  Such communication shall, when taken in
conjunction with the Offer, be deemed to constitute a valid, legally binding and
enforceable agreement for the sale and purchase of such Offered Shares (subject
to the aforesaid limitations as to a Purchaser's right to purchase more than its
Pro Rata Fraction).  Sales of the Offered Shares to be sold to purchasing
Purchasers pursuant to this Section 10 shall be made at the offices of the
Corporation on the 45th day following the date the Offer was made (or if such
45th day is not a business day, then on the next succeeding business day).  Such
sales shall be effected by Founder's delivery to each purchasing Purchaser of a
certificate or certificates evidencing the Offered Shares to be purchased by it,
free and clear of any liens, claims or encumbrances of any kind (other than
pursuant to this Agreement), duly endorsed for transfer to such purchasing
Purchaser and with any requisite stock transfer stamps attached, against payment
to Founder of the purchase price therefor by such purchasing Purchaser.

     (E) If the Purchasers do not purchase all of the Offered Shares, the
Offered Shares may be sold by Founder at any time within six months after the
date the Offer was made, subject to Section 11 below and the other provisions of
this Agreement.  Any such sale shall be to the Proposed Transferee, at not less
than the price and upon other terms

                                       6
<PAGE>

and conditions, if any, not more favorable to the Proposed Transferee than those
specified in the Offer. Any Offered Shares not sold within such six-month period
shall continue to be subject to the requirements of a prior offer pursuant to
this Section 10.

     11.  Co-Sale Rights.  (A) If at any time a Purchaser desires to sell all or
any part of its Common Stock or Preferred Stock ("Purchaser's Shares") pursuant
to a bona fide offer from a third party (for purposes of this Section 11, also a
"Proposed Transferee"), such Purchaser shall deliver a written notice (the
"Notice") of such proposed sale of such Purchaser's Shares (for purposes of this
Section 11, also "Offered Shares") to the other Purchaser.  The Notice shall
disclose the identity of the Proposed Transferee, the Offered Shares proposed to
be sold, the total number of Purchaser's Shares owned by such Purchaser, the
terms and conditions, including price, of the proposed sale, that the proposed
buyer has been informed of the rights and obligations provided for in this
Section 11 and has agreed to purchase Offered Shares in accordance with the
terms of this Agreement, and any other material facts relating to the proposed
sale.

     (B) (i) If a Purchaser elects not to purchase any Offered Shares pursuant
to Section 10 above; or (ii) if upon receipt of a Notice pursuant to Section
11(A) above, such Purchaser desires to sell any of such Purchaser's Shares, then
such Purchaser shall have the right, exercisable upon written notice (the "Co-
Sale Acceptance Notice") to the selling Founder or Purchaser, as applicable,
given within thirty (30) days after the Offer or Notice, as applicable has been
delivered pursuant to Section 10 or 11(A) above, to participate in the proposed
sale of Offered Shares pursuant to the terms and conditions specified in the
Offer or Notice, as applicable, and the selling Founder or Purchaser, as
applicable, shall require the Proposed Transferee designated in the Offer or
Notice, as applicable, to purchase from such Founder or Purchaser up to the
number of whole shares of Common Stock or Preferred Stock, as applicable, equal
to the product of (i) the total number of Offered Shares to be transferred in
such proposed sale as specified in the Offer or Notice, as applicable, and (ii)
a fraction, the numerator of which (a) in the case of Offered Shares which are
Common Stock, is the number of outstanding shares of Common Stock held by such
Purchaser (including any Common Stock issuable to such Purchaser upon the
conversion or exchange of any Purchaser's Shares convertible or exchangeable
into Common Stock) or (b) in the case of Offered Shares which are Preferred
Stock, is the number of outstanding shares of Preferred Stock held by such
Purchaser, and the denominator of which (c) in the case of Offered Shares which
are Common Stock, is the total number of shares of Common Stock (on a fully-
diluted basis) then outstanding or (d) in the case of Offered Shares which are
Preferred Stock, is the total number of shares of Preferred Stock (on a fully-
diluted basis) then outstanding . The Co-Sale Acceptance Notice shall state the
number of shares such Purchaser proposes to include in such proposed sale to the
Proposed Transferee (up to the number of shares as calculated pursuant to the
immediately preceding sentence).  Any such sale by such Purchaser shall be at
the same price per share (including price and type of consideration) received by
the Proposed Transferee and otherwise on identical terms and conditions as

                                       7
<PAGE>

received by the selling Founder or Purchaser, as the case may be, in its sale to
the Proposed Transferee.  In the event that the Proposed Transferee does not
purchase shares of Common Stock and/or Preferred Stock from Purchasers who have
timely delivered a Co-Sale Acceptance Notice as required by this Section 11,
then the selling Founder or Purchaser, as the case may be, shall not be
permitted to, and shall not, sell any Offered Shares to the Proposed Transferee
in the proposed sale.

     (C) If no Co-Sale Acceptance Notice is received by the selling Founder or
Purchaser, as the case may be, during the 30-day period referred to in Section
11(A) above, then such Founder or Purchaser, as the case may be, shall have the
right to sell the Offered Shares at any time within six months after the date
the Offer or Notice, as the case may be was delivered, subject to the other
provisions of this Agreement.  Any such sale shall be to the Proposed
Transferee, at not less than the price and upon other terms and conditions, if
any, not more favorable to the Proposed Transferee than those specified in the
Offer or Notice, as applicable.  Any Offered Shares not sold within such six-
month period shall continue to be subject to the requirements of Section 10 and
this Section 11.

     (D) Notwithstanding the foregoing, this Section 11 shall not apply to any
Transfer by any Purchaser or Founder of Shares:  (i) to such Purchaser's or
Founder's affiliates, members of such Purchaser's or Founder's immediate family,
family trusts or Purchasers, (ii) constituting a gift or gifts, or (iii)
constituting less than 1% of the outstanding class of Shares to be Transferred.

     12.  Termination.  The Corporation's right to repurchase Vested Shares
pursuant to Section 8 hereof, and the provisions of Sections 7, 9, 10, 11 and 13
hereof, shall terminate immediately upon the closing of a firm commitment,
underwritten public offering registered under the Securities Act, (other than a
registration relating solely to a transaction referred to in Rule 145 under the
Securities Act (or any successor rule) or to an employee benefit plan of the
Corporation), at a public offering price (prior to underwriters' discounts and
expenses) equal to or exceeding $2.50 per share of Common Stock (as adjusted for
any stock dividends, combinations or splits with respect to such shares) and in
which the aggregate proceeds to the Corporation and/or selling stockholders
(before deduction for underwriters' discounts and expenses relating to the
issuance, including without limitation fees of the Corporation's counsel) exceed
$5,000,000.

     13.  Failure to Deliver Shares.  If Founder becomes obligated to sell any
Founder's Shares to a Purchaser or the Corporation under this Agreement and
fails to deliver such Founder's Shares in accordance with the terms of this
Agreement, such Purchaser or the Corporation, as the case may be, may, at its
option, in addition to all other remedies it may have, send to Founder the
purchase price for such Founder's Shares as is herein specified.  Thereupon, the
Corporation upon written notice to Founder, (i) shall cancel on its books the
certificate or certificates representing the Founder's Shares to be sold and
(ii) shall issue, in lieu thereof, in the name of such

                                       8
<PAGE>

Purchaser or the corporation, as the case may be, a new certificate or
certificates representing such Founder's Shares, and thereupon all of Founder's
rights in and to such Founder's Shares shall terminate.

     14.  Lock-up.  If requested by the underwriters for the initial
underwritten public offering of securities of the Corporation, Founder and each
Purchaser shall agree not to sell, assign, transfer, pledge, hypothecate,
mortgage, encumber or otherwise dispose of all or any of such Founder's or
Purchaser's Shares, without the written consent of such underwriters, for a
period of not more than 180 days following the effective date of the
registration statement relating to such offering.  This Section 14 shall
expressly survive the termination of this Agreement.

     15.  No Waiver.  Any waiver of a breach of any of the terms of this
Agreement shall not operate as a waiver of any other breach of such terms or
conditions or any other terms or conditions, nor shall any failure to enforce
any provision of this Agreement operate as a waiver of such provision or any
other provision.

     16.  Successors and Assigns.  The rights, benefits and obligations of the
Corporation under this Agreement and all covenants and agreements hereunder
shall inure to the benefit of and be enforceable by or against its successors
and assigns.  Subject to the limitations set forth herein, this Agreement shall
inure to the benefit of and be binding upon the Founders' heirs, successors and
assigns.  Subject to the limitations set forth herein, neither this Agreement
nor any rights or obligations hereunder shall be assigned by any Founder.  The
rights of the Purchasers hereunder shall inure to the benefit of and be binding
upon the Purchasers respective successors and assigns.

     17.  Entire Agreement.  The Agreement (with respect to the Corporation and
the Purchasers, together with the Purchase Agreement), constitutes the entire
agreement among the parties.  This Founders Agreement may not be amended or
modified, except in writing, and signed by each of the Purchasers and Founder.

     18.  Severability.  If any provision of this Agreement or the application
thereof is held invalid or unenforceable, the invalidity or unenforceability
thereof shall not affect any other provisions or applications of this Agreement
which can be given effect without the invalid or unenforceable provision or
application.  To that end, the provisions of this Agreement are to be severable.

     19.  Governing Law.  This Agreement shall be governed by and construed in
accordance with the internal laws of the State of New York (without giving
effect to its conflicts of laws principles).

                 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       9
<PAGE>

     IN WITNESS WHEREOF. the Corporation has caused this Agreement to be signed
and each Founder has executed this Agreement as of the date shown below.

                                GENOMICA CORPORATION

Dated:__________, 1996          BY:     /s/ James L. Rathmanns
                                   ------------------------------------
                                TITLE:_________________________________

Dated: March 22 , 1996          FOUNDER:  /s/ Steven Cozza
       ---------                        -------------------------------
                                           Steven Cozza

                                PURCHASERS:

                                FALCON TECHNOLOGY PARTNERS, L.P.
                                        A Delaware limited partnership

                                BY:     /s/ James L. Rathmann
                                   ------------------------------------
                                TITLE:  General Partner

                                HARRIS & HARRIS GROUP, INC.
                                        A NY corporation

                                BY:     /s/ D.C.J.
                                   ------------------------------------
                                TITLE:  Executive Vice President
                                      ---------------------------------

                                       10
<PAGE>

                                  SCHEDULE 1
                                  ----------

Founder         Founders'       Vesting Schedule
-------         ---------       ----------------
                Shares
                ------
Cozza           30,000          15,000 shares become Vested Shares on the date
                ($30.00)        hereof and the remaining shares become Vested
                                Shares on the first anniversary of the date
                                hereof; provided however, that notwithstanding
                                the above provisions, if Cozza leaves the employ
                                of CSH for any reason except to become an
                                employee of the Company, all shares which have
                                not yet become Vested Shares will always remain
                                Unvested Shares.

                                       11
<PAGE>

                                   Exhibit A

                           CONFIDENTIALITY AGREEMENT
                           -------------------------

Name:         Steven Cozza              Employment Date:       July 6, 1990
     ------------------------------                     ------------------------
             (Type or Print)

        In consideration of (i) Genomica Corporation (the "Company") entering
into certain agreements and arrangements with my employer, Cold Spring Harbor
Laboratory ("Cold Spring Harbor"), whereby the Company will, among other things,
sponsor certain research activities in which I may be involved, and (ii) the
Company's issuance and sale to me of shares of its common stock pursuant to a
Common Stock Acquisition Agreement between the Company and me, and for other
good and valuable consideration, the receipt and sufficiency of which are by
acknowledged, I understand and agree to the following provisions for the
protection of the confidential information of the Company.

        1.  Confidentiality.  I agree that without the written permission of the
Company, I will not knowingly use, publish or otherwise disclose any
Confidential Information. The term "Confidential Information" means any
Proprietary Information or any knowledge, information or materials about the
products, services, know-how, research and development, customers, or business
plans of the Company or any confidential information about financial matters,
marketing, pricing, compensation or any other confidential information of the
Company, its customers, or others from whom the Company has received information
under obligations of confidence which have been communicated to me in writing.
The term "Proprietary Information" means all intellectual and/or physical work
product, including without limitation, inventions, whether or not patentable and
whether or not tested or reduced to practice, discoveries, ideas, conceptions,
processes, developments, designs, business plans, trade secrets, mask works,
know-how and tangible expressions, whether or not copyrightable, computer
software, systems, programs or procedures, which (a) relates to the actual or
anticipated business activities of the Company, (b) results from work which is
performed for the Company or which is funded in whole or in part by the Company
or (c) results from any use of premises, equipment or property (tangible or
intangible) owned, leased, licensed or contracted for by the Company.
Notwithstanding the foregoing provisions of this paragraph 1 to the contrary,
"Confidential information" shall not include any information which (i) has been
made available to the general public of information which subsequently comes in
the public domain through no fault or omissions by me, (ii) is subsequently
disclosed by a third party which has the bona fide right to make such
disclosure, (iii) is required to be disclosed by law or a governmental agency
and (iv) is already generally known by personas in the computer software
industry or developed by
<PAGE>

Genomica Corporation
Confidentiality Agreement
Page 2

me independent of my work with the Company or Cold Spring Harbor without use of
any Confidential Information.

        2.  Confidential Information of Others.  I agree not to knowingly
disclose to the Company (a) any confidential information belonging to others or
(b) any prior inventions made by me which the Company is not entitled to learn
of or use.

        3.  Return of Materials.  Upon the written request of the Company at any
time, I will deliver promptly to the Company all documents, materials and things
(if any) in my possession which belong to the Company or have been given to me
by the Company.

        4.  Prior Agreements.  I represent that I have attached hereto a copy of
any agreement (such as a prior employment agreement) which affects my ability to
comply with the terms of this Agreement. If there is no such agreement, I have
written my initials here:  SC
                          ----

        5.  Enforcement.  I agree that the Company would not be fairly
compensated by money damages for any breach of this Agreement by me and
therefore, in the event of a breach or threatened breach of this Agreement, the
Company shall be entitled to specific performance, an injunction and other
equitable relief in addition to money damages and other legal remedies.
<PAGE>

Genomica Corporation
Confidentiality Agreement
Page 3

        6.  Miscellaneous.  This Agreement shall be binding on my executors,
administrators, heirs, legal representatives or assigns, and may not be modified
except in writing with the approval of a duly authorized officer of the Company.
If any provision of this Agreement is determined to be illegal or unenforceable,
because of the duration thereof or the area or scope covered, I hereby request
any court making such determination to reduce the duration, area and/or scope so
that in its reduced form such covenant shall be enforceable and I agree that in
such event all remaining provisions shall remain in full force and effect. This
Agreement shall be governed and construed in accordance with the internal laws
of the State of New York. This document sets forth the entire agreement between
the Company and me with respect to the matters set forth herein.

WITNESS:                                     EMPLOYEE:

        /s/ Eric Hackborn                              /s/ Steven Cozza
-----------------------------------          -----------------------------------
Eric Hackborn                                Steven Cozza

Date:         3-22-96                        Date:          3/22/96
     ------------------------------               ------------------------------

                                             Social Security No.   ###-##-####
                                                                ----------------
<PAGE>

                             GENOMICA CORPORATION
                              FOUNDERS AGREEMENT

     THIS AGREEMENT is made as of the 22 th day of March, 1996, by and among
Genomica Corporation, a Delaware corporation, (the "Corporation"), Donald Fisher
("Founder") and the persons (the "Purchasers") named in Schedule I to a certain
Series A Convertible Preferred Stock Purchase Agreement of the Corporation dated
the date hereof (the "Purchase Agreement").

                                   RECITALS
                                   --------

     The Corporation is engaged in the highly competitive business of
researching, developing, manufacturing and marketing computer software for the
biotechnology industry on an international basis.  Founder and the Corporation
recognize and affirm that success or failure in this highly technical and highly
competitive business is dependent on the ability of the Corporation to (1)
develop and protect proprietary technology which will give the Corporation a
competitive advantage in the marketplace; (2) incorporate this technology into
products which themselves will or may become proprietary; and (3) develop and
utilize processes which may be proprietary to accomplish (1) and (2) above.

     In order to achieve the above objectives, the Corporation has expended and
will continue to expend substantial time, effort and financial resources.  These
activities include research, the attraction and training of key employees, and
establishing relationships with necessary resources outside the Corporation.  If
information regarding the Corporation's research, processes or products were to
fall into the hands of a competitor of the Corporation, it could be used in a
manner which would cause serious and irreparable financial and business damage
to the Corporation.  For this reason, all information related to the
Corporation's technology, research, products, and business strategies is
considered to be confidential information which is proprietary to the
Corporation.

     In addition, the Purchasers intend to invest in the Corporation pursuant to
the Purchase Agreement based on the foregoing assumptions and such investment is
contingent upon the execution and delivery of this Agreement by the Corporation
and Founder.

                                   AGREEMENT
                                   ---------

     NOW, THEREFORE, in consideration of the above representations and
understandings, and the promises and mutual agreements set forth below, the
parties agree, effective on the date of the Agreement, to the following terms
and conditions:

                                       1
<PAGE>

     1.  Services.  Founder agrees to serve the Corporation as reasonably
directed by its Board of Directors or its designee, consistent with the scope of
expertise and other employment obligations of Founder.  Such services may
include participation in the Corporation as a director, officer, scientific
advisor, consultant, contractor and/or, with the agreement of Founder, an
employee.  In all such cases, the terms and conditions of this Agreement will
continue to be binding.

     2.  Founder's Stock.  Founder has purchased from the Corporation an
aggregate of 250,000 shares of Common Stock (the "Shares") at a per-share
purchase price of $.001 (the "Original Purchase Price") as more specifically set
forth on Schedule 1 hereto.  Founder's Shares shall be subject to a number of
restrictions as set forth in this Agreement.  Certain of the restrictions with
respect to Founder's Shares may terminate under various conditions pursuant
hereto in consideration for Founder's service to the Corporation as described
herein.

     3.  [INTENTIONALLY OMITTED]

     4.  Disclosure and Assignment of Technology to Corporation.  Concurrently
with the execution of this Agreement, Founder is executing and delivering a
Nondisclosure and Developments Agreement substantially in the form set forth as
Exhibit A hereto (the "Nondisclosure and Developments Agreement").

     5.  [INTENTIONALLY OMITTED]

     6.  Remedies in the Event of Breach.  The Corporation, the Purchasers and
Founder understand and agree that any breach or threatened breach by the
Corporation or Founder of any of the provisions hereof cannot be remedied solely
by the recovery of damages, and in the event of any such breach or threatened
breach, the Corporation or the Purchasers, as the case may be, shall be entitled
to injunctive relief, restraining Founder, and any business, firm, corporation,
individual or other entity participating in such breach or attempted breach from
engaging in any activity which would constitute a breach.  The Corporation, the
Purchasers and Founder further agree that any dispute arising under the terms of
this Agreement shall be decided in accordance with the rules then in effect of
the American Arbitration Association, and any arbitration award may be entered
in a court of competent jurisdiction and enforced as a judgment thereof.
Nothing herein, however, shall be construed as (i) prohibiting the Corporation,
the Purchasers or Founder from pursuing, in conjunction with an injunction or
otherwise, any other remedies available in equity or at law for any such breach
or threatened breach, including the recovery of damages; or (ii) limiting the
Corporation's remedy against Founder as set forth in Section 13 below.

     7.  Transferability.  The Corporation and Founder agree (i) that Unvested
Shares (as defined below) may not be sold, pledged or otherwise transferred
("Transferred") without the consent of the Board of Directors in its sole
discretion

                                       2
<PAGE>

(except pursuant to Section 9 below); and (ii) Vested Shares (as defined below)
may be Transferred only in accordance with the provisions set forth herein and
only if the transferee of such Vested Shares agrees in writing to be bound by
the provisions of Sections 9, 10, 11, 13 and 14 hereof. Any Founder's Shares
Transferred not in accordance with the preceding sentence shall be void, ab
initio.

     8.  Founder's Stock.  Founder's Shares shall be affected as follows:

     (A) In the event (i) Founder dies; (ii) of a breach by Founder of any of
the terms of the Nondisclosure and Developments Agreement or the Common Stock
Acquisition Agreement by which Founder purchased the Founder's Shares (any such
case, a "Discontinuation Event"), certain of Founder's Shares, defined below as
"Unvested Shares," shall be repurchased and paid for in full by the Corporation
at the Original Purchase Price within 30 days of such Discontinuation Event.
Unvested Shares shall be those Founder's Shares which have not yet vested
according to the schedule set forth in Schedule 1 hereto.  Notwithstanding the
preceding sentence, in the event the Corporation's Board of Directors approves a
sale or merger (other than a merger with or into a wholly-owned subsidiary of
the Corporation or a merger in which the Corporation is the surviving entity) of
the Corporation or an initial public offering of the Corporation's stock (any of
which events is defined herein as a "Triggering Transaction"), Founder will be
notified of such Board action.  Any of Founder's then Unvested Shares will
become Vested Shares (as defined below) simultaneously with the consummation of
the Triggering Transaction.  Upon the occurrence of a Discontinuation Event, all
of Founder's Unvested Shares shall forever remain Unvested Shares.

     (B) Upon the occurrence of a Discontinuation Event, Founder's Shares which
are vested pursuant to Schedule 1 hereto ("Vested Shares") may be repurchased by
the Corporation, solely at the option of the Corporation (the "Corporation
Option"), at Fair Market Value (as defined below).  The Corporation agrees to
give Founder (or his estate) notice of its intent to exercise the Corporation
Option within ninety (90) days of the date of such Discontinuation Event and to
pay for those shares for which it exercises such Corporation Option as follows:
3/24ths of the total price within 90 days of the date of the Discontinuation
Event, with the balance to be paid in equal monthly installments over the next
succeeding twenty-one months.

     (C) Termination For Cause.  Prior to the Corporation's initial public
offering, in the event of a Discontinuation Event with respect to Founder
occurring as a result of an event set forth in clause (ii) of Section 8(A)
above, then with respect to any of Founder's Shares not repurchased by the
Corporation pursuant to Sections 8(A) or 8(B) above, Founder shall, in all
matters put forth to a vote of the holders of Common Stock (i) cause such
Founder's Shares to be represented at any meeting of the stockholders of the
Corporation and (ii) vote such shares in the same proportion and in the same
manner as all other Common Stock is voted.

                                       3
<PAGE>

     (D) Fair Market Value.  For the purposes of Section 8(B), Fair Market Value
shall be that value as determined in good faith by the Board of Directors.  Any
Founder (or his estate) may request an appraisal by written notice of objection
delivered not later than fifteen (15) days after receipt of such Fair Market
Value determination by the Board of Directors.  If an appraisal is demanded, the
Corporation shall select an appraiser reasonably acceptable to Founder (or his
estate) to appraise Founder's Vested Shares, and the repurchase price payable
upon the Corporation's exercise of the Corporation Option shall be the higher of
such appraisal and such Fair Market Value determination by the Board of
Directors.  If such appraisal results in a valuation more than 10% higher than
the Fair Market Value determination by the Board of Directors, then all expenses
of such appraisal shall be paid by the Corporation; otherwise, all expenses of
such appraisal shall be paid by Founder (or his estate).

     9.  Approved Sale of Corporation.  (A) If the Corporation's Board of
Directors has adopted a resolution of the Board of Directors approving the sale
of the Corporation to any person (such person, the "Acquiring Entity"), whether
by merger, consolidation, sale of all or substantially all of the Corporation's
assets or sale of all of the outstanding capital stock (such sale, an "Approved
Sale"), Founder and each Purchaser will consent to, vote for and raise no
objections against the Approved Sale, and if the Approved Sale is structured as
a sale of stock, Founder and each Purchaser hereby agrees to sell all of their
respective Shares (and all rights thereto) on the terms and conditions approved
by the Board of Directors, provided that each holder of Common Stock receives in
the Approved Sale the same amount and type of consideration for its interest in
the Corporation as is received by the holders of the Series A Convertible
Preferred Stock, (the "Preferred Stock"), assuming such holders had converted
their respective shares of Preferred Stock into Common Stock.  Founder and each
Purchaser will take all actions reasonably required to facilitate and consummate
an Approved Sale of the Corporation.

     (B) The Corporation shall give written notice (a "Sale Notice") of any such
Approved Sale to Founder and Purchasers.  A Sale Notice shall contain  (i) the
name and address of the prospective Acquiring Entity; (ii) the purchase price
and other material terms and conditions of the Approved Sale; (iii) the date on
which the Approved Sale is intended to be consummated; (iv) the date on which
the Corporation's Board of Directors approved the Approved Sale and (v) the
Founder's and Purchaser's Shares proposed to be sold.  Upon receipt of a Sale
Notice, Founder and each Purchaser shall be required to consent to such Approved
Sale and to sell its Founder's or Purchaser's Shares, as the case may be, to the
Acquiring Entity designated therein within 30 days of receipt thereof or such
later date as may be specified in the Sale Notice.  No Purchaser or Founder
shall be required to make any representations and warranties other than
representations and warranties concerning its ownership of such Founder's or
Purchaser's Shares, the absence of any liens or encumbrances thereon and its
authority to sell such Shares; and provided further that, if the terms of such
Approved Sale provide for the escrow of any amount of proceeds resulting from an
Approved Sale or to accept indebtedness or other securities

                                       4
<PAGE>

subject to indemnification or other rights of offset, then Founder and
Purchasers shall be required to escrow a pro rata amount of its proceeds from
such Approved Sale and/or to accept such indebtedness or other securities.

     (C) If the Corporation or Founder, in connection with any Approved Sale,
enters into any negotiation or transaction for which Rule 506 (or any similar
rule then in effect) promulgated by the Securities and Exchange Commission under
the Securities Act may be available with respect to such negotiation or
transaction (including a merger, consolidation or other reorganization), Founder
will at the request of the Corporation, appoint a purchaser representative (as
such term is defined in Rule 501(h) promulgated by the Securities and Exchange
Commission under the Securities Act) reasonably acceptable to the Corporation.
If Founder appoints the purchaser representative designated by the Corporation,
the Corporation will pay the fees of such purchaser representative, but if
Founder declines to appoint the purchaser representative designated by the
Corporation, Founder will appoint another purchaser representative (reasonably
acceptable to the Corporation), and Founder will be responsible for the fees of
the purchaser representative so appointed.

     10.  Right of First Refusal.  (A) Except pursuant to Section 9 above, if at
any time Founder desires to sell for cash all or any part of Founder's Shares
pursuant to a bona fide offer from a third party (the "Proposed Transferee"),
Founder shall submit a written offer (the "Offer") to sell Founder's Shares (the
"Offered Shares") to the Purchasers on terms and conditions, including price,
not less favorable to the Purchasers than those on which Founder proposes to
sell such Offered Shares to the Proposed Transferee.  The Offer shall disclose
the identity of the Proposed Transferee, the Offered Shares proposed to be sold,
the total number of Founder's Shares owned by Founder, the terms and conditions,
including price, of the proposed sale, that the proposed buyer has been informed
of the rights and obligations provided for in this Section 10 and Section 11
below and has agreed to purchase Offered Shares in accordance with the terms of
this Agreement, and any other material facts relating to the proposed sale.  The
Offer shall further state that the Purchasers may acquire, in accordance with
the provisions of this Agreement, all but not less than all of the Offered
Shares for the price and upon the other terms and conditions, including deferred
payment (if applicable), set forth therein.

     (B) Each Purchaser shall have the absolute right to purchase that number of
Offered Shares as shall be equal to the number of Offered Shares multiplied by a
fraction, the numerator of which shall be the number of Purchasers' Shares (as
defined below) then owned by such Purchaser and the denominator of which shall
be the aggregate number of Purchasers' Shares then owned by all of the
Purchasers.  For purposes of this Section 10, all of the securities of the
Corporation which a Purchaser has acquired, or has the right to acquire from the
Corporation, upon the conversion, exercise or exchange of any of the securities
of the Corporation then owned by such Purchaser shall be deemed to be
Purchasers' Shares then owned by such Purchaser.  (The amount of Offered Shares

                                       5
<PAGE>

that each Purchaser is entitled to purchase under this Section 10(B) shall be
referred to as its "Pro Rata Fraction").

     (C) The Purchasers shall have a right of oversubscription such that if any
Purchaser fails to accept the Offer as to its Pro Rata Fraction, the other
Purchasers shall, among them, have the right to purchase up to the balance of
the Offered Shares not so purchased.  Such right of oversubscription may be
exercised by a Purchaser by accepting the Offer as to more than its Pro Rata
Fraction.  If, as a result thereof, such oversubscriptions exceed the total
number of Offered Shares available in respect of such oversubscription
privilege, the oversubscribing Purchasers shall be cut back with respect to
their oversubscriptions on a pro rata basis in accordance with their respective
Pro Rata Fractions or as they may otherwise agree among themselves.  In the
event that the Purchasers in the aggregate shall not have elected in the manner
set forth below to purchase all of the Offered Shares, the Purchasers shall not
have the right to purchase any of the Offered Shares and the Founder shall have
the right to sell the Offered Shares in accordance with Section 10(E) below.

     (D) If the Purchasers, in the aggregate, desire to purchase all of the
Offered Shares, such Purchaser(s) shall communicate in writing their election to
purchase to Founder, which communication shall state the number of Offered
Shares each Purchaser desires to purchase (which shall in the aggregate be equal
to all the Offered Shares) and shall be given to Founder within thirty days of
the date the Offer was made.  Such communication shall, when taken in
conjunction with the Offer, be deemed to constitute a valid, legally binding and
enforceable agreement for the sale and purchase of such Offered Shares (subject
to the aforesaid limitations as to a Purchaser's right to purchase more than its
Pro Rata Fraction).  Sales of the Offered Shares to be sold to purchasing
Purchasers pursuant to this Section 10 shall be made at the offices of the
Corporation on the 45th day following the date the Offer was made (or if such
45th day is not a business day, then on the next succeeding business day).  Such
sales shall be effected by Founder's delivery to each purchasing Purchaser of a
certificate or certificates evidencing the Offered Shares to be purchased by it,
free and clear of any liens, claims or encumbrances of any kind (other than
pursuant to this Agreement), duly endorsed for transfer to such purchasing
Purchaser and with any requisite stock transfer stamps attached, against payment
to Founder of the purchase price therefor by such purchasing Purchaser.

     (E) If the Purchasers do not purchase all of the Offered Shares, the
Offered Shares may be sold by Founder at any time within six months after the
date the Offer was made, subject to Section 11 below and the other provisions of
this Agreement.  Any such sale shall be to the Proposed Transferee, at not less
than the price and upon other terms and conditions, if any, not more favorable
to the Proposed Transferee than those specified in the Offer.  Any Offered
Shares not sold within such six-month period shall continue to be subject to the
requirements of a prior offer pursuant to this Section 10.

                                       6
<PAGE>

     11.  Co-Sale Rights.  (A) If at any time a Purchaser desires to sell all or
any part of its Common Stock or Preferred Stock ("Purchaser's Shares") pursuant
to a bona fide offer from a third party (for purposes of this Section 11, also a
"Proposed Transferee"), such Purchaser shall deliver a written notice (the
"Notice") of such proposed sale of such Purchaser's Shares (for purposes of this
Section 11, also "Offered Shares") to the other Purchaser.  The Notice shall
disclose the identity of the Proposed Transferee, the Offered Shares proposed to
be sold, the total number of Purchaser's Shares owned by such Purchaser, the
terms and conditions, including price, of the proposed sale, that the proposed
buyer has been informed of the rights and obligations provided for in this
Section 11 and has agreed to purchase Offered Shares in accordance with the
terms of this Agreement, and any other material facts relating to the proposed
sale.

     (B) (i) If a Purchaser elects not to purchase any Offered Shares pursuant
to Section 10 above; or (ii) if upon receipt of a Notice pursuant to Section
11(A) above, such Purchaser desires to sell any of such Purchaser's Shares, then
such Purchaser shall have the right, exercisable upon written notice (the "Co-
Sale Acceptance Notice") to the selling Founder or Purchaser, as applicable,
given within thirty (30) days after the Offer or Notice, as applicable has been
delivered pursuant to Section 10 or 11(A) above, to participate in the proposed
sale of Offered Shares pursuant to the terms and conditions specified in the
Offer or Notice, as applicable, and the selling Founder or Purchaser, as
applicable, shall require the Proposed Transferee designated in the Offer or
Notice, as applicable, to purchase from such Founder or Purchaser up to the
number of whole shares of Common Stock or Preferred Stock, as applicable, equal
to the product of (i) the total number of Offered Shares to be transferred in
such proposed sale as specified in the Offer or Notice, as applicable, and (ii)
a fraction, the numerator of which (a) in the case of Offered Shares which are
Common Stock, is the number of outstanding shares of Common Stock held by such
Purchaser (including any Common Stock issuable to such Purchaser upon the
conversion or exchange of any Purchaser's Shares convertible or exchangeable
into Common Stock) or (b) in the case of Offered Shares which are Preferred
Stock, is the number of outstanding shares of Preferred Stock held by such
Purchaser, and the denominator of which (c) in the case of Offered Shares which
are Common Stock, is the total number of shares of Common Stock (on a fully-
diluted basis) then outstanding or (d) in the case of Offered Shares which are
Preferred Stock, is the total number of shares of Preferred Stock (on a fully-
diluted basis) then outstanding . The Co-Sale Acceptance Notice shall state the
number of shares such Purchaser proposes to include in such proposed sale to the
Proposed Transferee (up to the number of shares as calculated pursuant to the
immediately preceding sentence).  Any such sale by such Purchaser shall be at
the same price per share (including price and type of consideration) received by
the Proposed Transferee and otherwise on identical terms and conditions as
received by the selling Founder or Purchaser, as the case may be, in its sale to
the Proposed Transferee.  In the event that the Proposed Transferee does not
purchase shares of Common Stock and/or Preferred Stock from Purchasers who have
timely delivered a Co-Sale Acceptance Notice as required by this Section 11,
then the selling Founder or

                                       7
<PAGE>

Purchaser, as the case may be, shall not be permitted to, and shall not, sell
any Offered Shares to the Proposed Transferee in the proposed sale.

     (C) If no Co-Sale Acceptance Notice is received by the selling Founder or
Purchaser, as the case may be, during the 30-day period referred to in Section
11(A) above, then such Founder or Purchaser, as the case may be, shall have the
right to sell the Offered Shares at any time within six months after the date
the Offer or Notice, as the case may be was delivered, subject to the other
provisions of this Agreement.  Any such sale shall be to the Proposed
Transferee, at not less than the price and upon other terms and conditions, if
any, not more favorable to the Proposed Transferee than those specified in the
Offer or Notice, as applicable.  Any Offered Shares not sold within such six-
month period shall continue to be subject to the requirements of Section 10 and
this Section 11.

     (D) Notwithstanding the foregoing, this Section 11 shall not apply to any
Transfer by any Purchaser or Founder of Shares:  (i) to such Purchaser's or
Founder's affiliates, members of such Purchaser's or Founder's immediate family,
family trusts or Purchasers, (ii) constituting a gift or gifts, or (iii)
constituting less than 1% of the outstanding class of Shares to be Transferred.

     12.  Termination.  The Corporation's right to repurchase Vested Shares
pursuant to Section 8 hereof, and the provisions of Sections 7, 9, 10, 11 and 13
hereof, shall terminate immediately upon the closing of a firm commitment,
underwritten public offering registered under the Securities Act, (other than a
registration relating solely to a transaction referred to in Rule 145 under the
Securities Act (or any successor rule) or to an employee benefit plan of the
Corporation), at a public offering price (prior to underwriters' discounts and
expenses) equal to or exceeding $2.50 per share of Common Stock (as adjusted for
any stock dividends, combinations or splits with respect to such shares) and in
which the aggregate proceeds to the Corporation and/or selling stockholders
(before deduction for underwriters' discounts and expenses relating to the
issuance, including without limitation fees of the Corporation's counsel) exceed
$5,000,000.

     13.  Failure to Deliver Shares.  If Founder becomes obligated to sell any
Founder's Shares to a Purchaser or the Corporation under this Agreement and
fails to deliver such Founder's Shares in accordance with the terms of this
Agreement, such Purchaser or the Corporation, as the case may be, may, at its
option, in addition to all other remedies it may have, send to Founder the
purchase price for such Founder's Shares as is herein specified.  Thereupon, the
Corporation upon written notice to Founder, (i) shall cancel on its books the
certificate or certificates representing the Founder's Shares to be sold and
(ii) shall issue, in lieu thereof, in the name of such Purchaser or the
corporation, as the case may be, a new certificate or certificates representing
such Founder's Shares, and thereupon all of Founder's rights in and to such
Founder's Shares shall terminate.

                                       8
<PAGE>

     14.  Lock-up.  If requested by the underwriters for the initial
underwritten public offering of securities of the Corporation, Founder and each
Purchaser shall agree not to sell, assign, transfer, pledge, hypothecate,
mortgage, encumber or otherwise dispose of all or any of such Founder's or
Purchaser's Shares, without the written consent of such underwriters, for a
period of not more than 180 days following the effective date of the
registration statement relating to such offering.  This Section 14 shall
expressly survive the termination of this Agreement.

     15.  No Waiver.  Any waiver of a breach of any of the terms of this
Agreement shall not operate as a waiver of any other breach of such terms or
conditions or any other terms or conditions, nor shall any failure to enforce
any provision of this Agreement operate as a waiver of such provision or any
other provision.

     16.  Successors and Assigns.  The rights, benefits and obligations of the
Corporation under this Agreement and all covenants and agreements hereunder
shall inure to the benefit of and be enforceable by or against its successors
and assigns.  Subject to the limitations set forth herein, this Agreement shall
inure to the benefit of and be binding upon the Founders' heirs, successors and
assigns.  Subject to the limitations set forth herein, neither this Agreement
nor any rights or obligations hereunder shall be assigned by any Founder.  The
rights of the Purchasers hereunder shall inure to the benefit of and be binding
upon the Purchasers respective successors and assigns.

     17.  Entire Agreement.  The Agreement (with respect to the Corporation and
the Purchasers, together with the Purchase Agreement), constitutes the entire
agreement among the parties.  This Founders Agreement may not be amended or
modified, except in writing, and signed by each of the Purchasers and Founder.

     18.  Severability.  If any provision of this Agreement or the application
thereof is held invalid or unenforceable, the invalidity or unenforceability
thereof shall not affect any other provisions or applications of this Agreement
which can be given effect without the invalid or unenforceable provision or
application.  To that end, the provisions of this Agreement are to be severable.

     19.  Governing Law.  This Agreement shall be governed by and construed in
accordance with the internal laws of the State of New York (without giving
effect to its conflicts of laws principles).

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       9
<PAGE>

     IN WITNESS WHEREOF. the Corporation has caused this Agreement to be signed
and each Founder has executed this Agreement as of the date shown below.

                                GENOMICA CORPORATION

Dated:__________, 1996          BY:     /s/ James L Rathmann
                                   ------------------------------------
                                TITLE:_________________________________

Dated:    3/15  , 1996          FOUNDER:  /s/ Donald Fisher
      ----------                        -------------------------------
                                              Donald Fisher

                                PURCHASERS:

                                FALCON TECHNOLOGY PARTNERS, L.P.
                                        A Delaware limited partnership

                                BY:  /s/ James L. Rathmann
                                   ------------------------------------
                                TITLE:  General Partner

                                HARRIS & HARRIS GROUP, INC.
                                        A NY corporation

                                BY:  /s/ D.C.J.
                                   ------------------------------------
                                TITLE:  Executive Vice President
                                      ---------------------------------

                                       10
<PAGE>

                                  SCHEDULE 1
                                  ----------

Founder       Founders'      Vesting Schedule
-------       ---------      -----------------
              Shares
              ------

Fisher        250,000        62,500 shares become Vested Shares on
              ($250.00)      September 25, 1996 and 1/36th of the remaining
                             shares become Vested Shares on the first day of
                             each calendar month commencing after such date;
                             provided however, that notwithstanding the above
                             provisions, if Fisher leaves the employ of the
                             Corporation for any reason, all shares which have
                             not yet become Vested Shares will always remain
                             Unvested Shares.

                                       11
<PAGE>

                           EMPLOYEE CONFIDENTIALITY
                                      AND
                  INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT
                  ------------------------------------------

Name:      Dr. Donald Fisher        Employment Date:           9/25/95
     -----------------------------                  ----------------------------
            (Type or Print)

          In consideration of my employment and the salary/wages paid to me by
Genomica Corporation, or any of its parent, subsidiary or affiliate companies
(all hereafter collectively called the "Company") and for other good and
valuable consideration, I understand and agree to the following provisions for
the protection of the property rights of the Company and for the protection of
the rights of others who have entrusted the Company with confidential
proprietary information:

          1.  Disclosure to the Company.  I agree to disclose fully and promptly
to the Company all Proprietary Information which is developed, conceived,
reduced to practice or learned by me solely or jointly with others, at any time
during the term of my employment.  I agree to make and maintain written records
of the aforesaid Proprietary Information and to submit promptly the same, and to
make supplemental oral disclosure, to the Company.  The term "Proprietary
Information" means all intellectual property and/or physical work product,
including without limitation, inventions, whether or not patentable and whether
or not tested or reduced to practice, discoveries, ideas, conceptions,
processes, developments, designs, business plans, trade secrets, mask works,
know-how and tangible expressions, whether or not copyrightable, computer
software, systems, programs or procedures, which (a) relates in any way to the
actual or anticipated business activities of the Company, (b) results from, or
is suggested by, work which is performed for the Company or which is funded in
whole or in part by the Company or (c) results from any use of premises,
equipment or property (tangible or intangible) owned, leased, licensed or
contracted for by the Company.

          2.  Ownership and Assignment of Assigned Intellectual Property.  I
agree to assign and hereby do assign to the Company as its exclusive property
the entire right, title and interest in and to all Proprietary Information
embraced by Paragraph 1 above, including without limitation, all patents, patent
applications and copyrights.  I further agree to execute all papers, and
otherwise to provide all requested assistance, at the Company's expense, during
and subsequent to my employment, to enable the Company or its nominees to obtain
such patents, copyrights and other legal protection as it may desire in any
country.  All copyrightable work ("Work") created by me in connection with my
employment is intended to be a "work made for hire" as that term is defined in
Section 101 of the Copyright Act of 1976, as amended (the "Copyright Act"), and
shall be the property of the Company, and the Company shall be the sole author
of such work within the meaning of the Copyright Act.  All such Works, as well
as copies of such Works in whatever medium fixed or embodied, shall be owned
exclusively by the

                                       12
<PAGE>

Genomica Corporation
Employee Confidentiality and Intellectual Property Agreement
Page 2

Company and I expressly disclaim any interest in them. If the copyright to any
such Works shall not be the property of the Company by operation of law, I
hereby assign and will assign to the Company, without further consideration, all
right, title and interest in such Work and will assist the Company, at its
expense, to secure, maintain and defend for the benefit of the Company all
copyrights, registrations, extensions and renewals on any and all such Work,
including translations thereof in any and all countries, such Work to be and
remain the property of the Company whether copyrighted or not.

          I hereby waive all moral rights and all inalienable rights that I may
have in any Work, including without limitation, any right to identification of
authorship, any right of approval on modifications or limitation on subsequent
modifications.  To the extent that this waiver is deemed unenforceable under
applicable law, I acknowledge and agree that I will not exercise any such
inalienable right without the specific prior written consent of the Company.

          In the event that the Company is unable, after reasonable effort, to
secure my signature on letters patent, copyright or other documents relating to
any Proprietary Information, whether because of my physical or mental incapacity
or for any other reason whatsoever, I hereby irrevocably designate and appoint
the Company and its duly authorized officers and agents as my agent and
attorney-in-fact, to act for and in my behalf and stead to execute and file any
such applications(s) and to take all other lawfully permitted acts to further
the prosecution and issuance of letters patent, copyright or other documents
with the same legal force and effect as if executed by me.

          The assignment provisions of this Agreement shall not apply to
Proprietary Information which is exempt from assignment under the applicable
laws of the state of employment.  I agree, however, that the Company shall have
a non-exclusive, fully paid license to use for all purposes any Proprietary
Information within the scope of the actual or anticipated business of the
Company but not assigned to the Company under this Agreement unless such a
license is prohibited by statute or by a court of last resort and final
jurisdiction.

          I understand and agree that the Company shall determine, in its sole
and absolute discretion, whether an application for or registration of any
patent, copyright or other intellectual property right shall be filed on any
development assigned to the Company under this Agreement, and whether such an
application shall be prosecuted or abandoned prior to issuance or registration.

          3.  Confidentiality.  I agree that without the written permission of
the Company, I will not either during or subsequent to my employment, use,
publish or otherwise disclose any Confidential Information except in the course
of my duties with and in furtherance of the business of the Company.  The term
"Confidential Information"

Employee's name: Dr. Donald Fisher
Employee Initial Here      DF
                         ------

                                       13
<PAGE>

Genomica Corporation
Employee Confidentiality and Intellectual Property Agreement
Page 3

means any Proprietary Information or any knowledge, information or materials
about the products, services, know-how, research and development, customers, or
business plans of the Company or any confidential information about financial
matters, marketing, pricing, compensation or any other confidential information
of the Company, its customers, or others from whom the Company has received
information under obligations of confidence.

          4.  Confidential Information of Others.  I agree not to disclose to
the Company, or to use in my work at the Company (a) any confidential
information belonging to others or (b) any prior inventions made by me which the
Company is not entitled to learn of or use. I represent that the inventions
identified in the _____ pages I attach hereto constitute all of the unpatented
inventions which I have made prior to my employment at the Company, which
inventions shall be excluded from this Agreement.  (It is only necessary to list
the title of such inventions and the purpose thereof.)  If there are no such
unpatented inventions, I have written my initials here:   DF  .
                                                        ------

          5.  Non-Solicitation.  During the term of my employment and for a
period of twelve (12) months thereafter I will not solicit or attempt to induce,
directly or indirectly, any employee or consultant of the Company to work with
me or any organization with which I may be affiliated or to accept a consulting
engagement or employment with a competitor, client or customer of the Company.

          6.  Return of Materials.  Upon the request of the Company at any time
and in the event of the termination of my employment at the Company, whether or
not such termination is voluntary, I will deliver promptly to my superior at the
Company, or to the Board of Directors of the Company, all documents which relate
to business activities of the Company, and all materials and things which belong
to the Company or have been given to me by the Company or others during the
course of my employment.

          7.  Prior Agreements.  I represent that I have attached hereto a copy
of any agreement (such as a prior employment agreement) which affects my ability
to comply with the terms of this Agreement.  If there is no such agreement, I
have written my initials here:   DF
                               ------

          8.  Enforcement.  I agree that the Company would not be fairly
compensated by money damages for any breach of this Agreement by me and
therefore, in the event of a breach or threatened breach of this Agreement, the
Company shall be entitled to specific performance, an injunction and other
equitable relief in addition to money damages and other legal remedies.  I
hereby waive any requirement that the Company post a bond or surety in
connection with its enforcement of this Agreement.

Employee's name: Dr. Donald Fisher
Employee Initial Here      DF
                         ------

                                       14
<PAGE>

Genomica Corporation
Consultant Confidentiality and Inventions Agreement
Page 4

          9.  Miscellaneous.   This Agreement shall be binding on my executors,
administrators, heirs, legal representatives or assigns, and may not be modified
except in writing with the approval of a duly authorized officer of the Company.
If any provision of this Agreement is determined to be illegal or unenforceable,
because of the duration thereof or the area or scope covered, I hereby request
any court making such determination to reduce the duration, area and/or scope so
that in its reduced form such covenant shall be enforceable and I agree that in
such event all remaining provisions shall remain in full force and effect.  This
Agreement shall be governed and construed in accordance with the internal laws
of the State of New York.  This agreement sets forth the entire agreement
between the Company and me with respect to the matters set forth herein.

WITNESS:                                     EMPLOYEE:

                                                      /s/ Donald Fisher
___________________________________          -----------------------------------

Date:______________________________          Date:           4/18/96
                                                  ------------------------------

                                             Social Security No.   ###-##-####
                                                                ----------------

                                       15
<PAGE>

                             GENOMICA CORPORATION
                              FOUNDERS AGREEMENT

     THIS AGREEMENT is made as of the 22 th day of March, 1996, by and among
Genomica Corporation, a Delaware corporation, (the "Corporation"), Dr. Thomas G.
Marr ("Founder") and the persons (the "Purchasers") named in Schedule I to a
certain Series A Convertible Preferred Stock Purchase Agreement of the
Corporation dated the date hereof (the "Purchase Agreement").

                                   RECITALS
                                   --------

     The Corporation is engaged in the highly competitive business of
researching, developing, manufacturing and marketing computer software for the
biotechnology industry on an international basis.  Founder and the Corporation
recognize and affirm that success or failure in this highly technical and highly
competitive business is dependent on the ability of the Corporation to (1)
develop and protect proprietary technology which will give the Corporation a
competitive advantage in the marketplace; (2) incorporate this technology into
products which themselves will or may become proprietary; and (3) develop and
utilize processes which may be proprietary to accomplish (1) and (2) above.

     In order to achieve the above objectives, the Corporation has expended and
will continue to expend substantial time, effort and financial resources.  These
activities include research, the attraction and training of key employees, and
establishing relationships with necessary resources outside the Corporation.  If
information regarding the Corporation's research, processes or products were to
fall into the hands of a competitor of the Corporation, it could be used in a
manner which would cause serious and irreparable financial and business damage
to the Corporation.  For this reason, all information related to the
Corporation's technology, research, products, and business strategies is
considered to be confidential information which is proprietary to the
Corporation.

     In addition, the Purchasers intend to invest in the Corporation pursuant to
the Purchase Agreement based on the foregoing assumptions and such investment is
contingent upon the execution and delivery of this Agreement by the Corporation
and Founder.

                                   AGREEMENT
                                   ---------

     NOW, THEREFORE, in consideration of the above representations and
understandings, and the promises and mutual agreements set forth below, the
parties agree, effective on the date of the Agreement, to the following terms
and conditions:
<PAGE>

     1.  Services.  Founder agrees to serve the Corporation as reasonably
directed by its Board of Directors or its designee, consistent with the scope of
expertise and other employment obligations of Founder.  Such services may
include participation in the Corporation as a director, officer, scientific
advisor, consultant, contractor and/or, with the agreement of Founder, an
employee. In all such cases, the terms and conditions of this Agreement will
continue to be binding.

     2.  Founder's Stock.  Founder has purchased from the Corporation an
aggregate of 1,080,000 shares of Common Stock (the "Shares") at a per-share
purchase price of $.001 (the "Original Purchase Price") as more specifically set
forth on Schedule 1 hereto.  Founder's Shares shall be subject to a number of
restrictions as set forth in this Agreement.  Certain of the restrictions with
respect to Founder's Shares may terminate under various conditions pursuant
hereto in consideration for Founder's service to the Corporation as described
herein.

     3.  Founder Consulting Agreement.  Concurrently with the execution of this
Agreement, Founder is executing and delivering a Consulting Agreement with the
Corporation substantially in the form set forth as Exhibit A hereto (the
"Consulting Agreement").

     4.  [INTENTIONALLY OMITTED]

     5.  [INTENTIONALLY OMITTED]

     6.  Remedies in the Event of Breach.  The Corporation, the Purchasers and
Founder understand and agree that any breach or threatened breach by the
Corporation or Founder of any of the provisions hereof cannot be remedied solely
by the recovery of damages, and in the event of any such breach or threatened
breach, the Corporation or the Purchasers, as the case may be, shall be entitled
to injunctive relief, restraining Founder, and any business, firm, corporation,
individual or other entity participating in such breach or attempted breach from
engaging in any activity which would constitute a breach.  The Corporation, the
Purchasers and Founder further agree that any dispute arising under the terms of
this Agreement shall be decided in accordance with the rules then in effect of
the American Arbitration Association, and any arbitration award may be entered
in a court of competent jurisdiction and enforced as a judgment thereof.
Nothing herein, however, shall be construed as (i) prohibiting the Corporation,
the Purchasers or Founder from pursuing, in conjunction with an injunction or
otherwise, any other remedies available in equity or at law for any such breach
or threatened breach, including the recovery of damages; or (ii) limiting the
Corporation's remedy against Founder as set forth in Section 13 below.

     7.  Transferability.  The Corporation and Founder agree (i) that Unvested
Shares (as defined below) may not be sold, pledged or otherwise transferred
("Transferred") without the consent of the Board of Directors in its sole
discretion

                                       2
<PAGE>

(except pursuant to Section 9 below); and (ii) Vested Shares (as defined below)
may be Transferred only in accordance with the provisions set forth herein and
only if the transferee of such Vested Shares agrees in writing to be bound by
the provisions of Sections 9, 10, 11, 13 and 14 hereof. Any Founder's Shares
Transferred not in accordance with the preceding sentence shall be void, ab
initio.

     8.  Founder's Stock.  Founder's Shares shall be affected as follows:

     (A) In the event (i) Founder dies; (ii) of a breach by Founder of any of
the terms of the Consulting Agreement or the Common Stock Acquisition Agreement
by which Founder purchased the Founder's Shares; or (iii) the Consulting
Agreement shall have been terminated by the Corporation for Due Cause (as such
term is defined in the Consulting Agreement) or if Dr. Marr voluntarily
terminates the Consulting Agreement (any such case, a "Discontinuation Event"),
certain of Founder's Shares, defined below as "Unvested Shares," shall be
repurchased and paid for in full by the Corporation at the Original Purchase
Price within 30 days of such Discontinuation Event.  Unvested Shares shall be
those Founder's Shares which have not yet vested according to the schedule set
forth in Schedule 1 hereto.  Notwithstanding the preceding sentence, in the
event the Corporation's Board of Directors approves a sale or merger (other than
a merger with or into a wholly-owned subsidiary of the Corporation or a merger
in which the Corporation is the surviving entity) of the Corporation or an
initial public offering of the Corporation's stock (any of which events is
defined herein as a "Triggering Transaction"), Founder will be notified of such
Board action.  Any of Founder's then Unvested Shares will become Vested Shares
(as defined below) simultaneously with the consummation of the Triggering
Transaction.  Upon the occurrence of a Discontinuation Event, all of Founder's
Unvested Shares shall forever remain Unvested Shares.

     (B) Upon the occurrence of a Discontinuation Event, Founder's Shares which
are vested pursuant to Schedule 1 hereto ("Vested Shares") may be repurchased by
the Corporation, solely at the option of the Corporation (the "Corporation
Option"), at Fair Market Value (as defined below).  The Corporation agrees to
give Founder (or his estate) notice of its intent to exercise the Corporation
Option within ninety (90) days of the date of such Discontinuation Event and to
pay for those shares for which it exercises such Corporation Option as follows:
3/24ths of the total price within 90 days of the date of the Discontinuation
Event, with the balance to be paid in equal monthly installments over the next
succeeding twenty-one months.

     (C) Termination For Cause.  Prior to the Corporation's initial public
offering, in the event of a Discontinuation Event with respect to Founder
occurring as a result of an event set forth in clauses (ii) or (iii) of Section
8(A) above, then with respect to any of Founder's Shares not repurchased by the
Corporation pursuant to Sections 8(A) or 8(B) above, Founder shall, in all
matters put forth to a vote of the holders of Common Stock (i) cause such
Founder's Shares to be represented at any meeting of the stockholders of

                                       3
<PAGE>

the Corporation and (ii) vote such shares in the same proportion and in the same
manner as all other Common Stock is voted.

     (D) Fair Market Value.  For the purposes of Section 8(B), Fair Market Value
shall be that value as determined in good faith by the Board of Directors.  Any
Founder (or his estate) may request an appraisal by written notice of objection
delivered not later than fifteen (15) days after receipt of such Fair Market
Value determination by the Board of Directors.  If an appraisal is demanded, the
Corporation shall select an appraiser reasonably acceptable to Founder (or his
estate) to appraise Founder's Vested Shares, and the repurchase price payable
upon the Corporation's exercise of the Corporation Option shall be the higher of
such appraisal and such Fair Market Value determination by the Board of
Directors.  If such appraisal results in a valuation more than 10% higher than
the Fair Market Value determination by the Board of Directors, then all expenses
of such appraisal shall be paid by the Corporation; otherwise, all expenses of
such appraisal shall be paid by Founder (or his estate).

     9.  Approved Sale of Corporation.  (A) If the Corporation's Board of
Directors has adopted a resolution of the Board of Directors approving the sale
of the Corporation to any person (such person, the "Acquiring Entity"), whether
by merger, consolidation, sale of all or substantially all of the Corporation's
assets or sale of all of the outstanding capital stock (such sale, an "Approved
Sale"), Founder and each Purchaser will consent to, vote for and raise no
objections against the Approved Sale, and if the Approved Sale is structured as
a sale of stock, Founder and each Purchaser hereby agrees to sell all of their
respective Shares (and all rights thereto) on the terms and conditions approved
by the Board of Directors, provided that each holder of Common Stock receives in
the Approved Sale the same amount and type of consideration for its interest in
the Corporation as is received by the holders of the Series A Convertible
Preferred Stock, (the "Preferred Stock"), assuming such holders had converted
their respective shares of Preferred Stock into Common Stock. Founder and each
Purchaser will take all actions reasonably required to facilitate and consummate
an Approved Sale of the Corporation.

     (B) The Corporation shall give written notice (a "Sale Notice") of any such
Approved Sale to Founder and Purchasers.  A Sale Notice shall contain  (i) the
name and address of the prospective Acquiring Entity; (ii) the purchase price
and other material terms and conditions of the Approved Sale; (iii) the date on
which the Approved Sale is intended to be consummated; (iv) the date on which
the Corporation's Board of Directors approved the Approved Sale and (v) the
Founder's and Purchaser's Shares proposed to be sold.  Upon receipt of a Sale
Notice, Founder and each Purchaser shall be required to consent to such Approved
Sale and to sell its Founder's or Purchaser's Shares, as the case may be, to the
Acquiring Entity designated therein within 30 days of receipt thereof or such
later date as may be specified in the Sale Notice.  No Purchaser or Founder
shall be required to make any representations and warranties other than

                                       4
<PAGE>

representations and warranties concerning its ownership of such Founder's or
Purchaser's Shares, the absence of any liens or encumbrances thereon and its
authority to sell such Shares; and provided further that, if the terms of such
Approved Sale provide for the escrow of any amount of proceeds resulting from an
Approved Sale or to accept indebtedness or other securities subject to
indemnification or other rights of offset, then Founder and Purchasers shall be
required to escrow a pro rata amount of its proceeds from such Approved Sale
and/or to accept such indebtedness or other securities.

     (C) If the Corporation or Founder, in connection with any Approved Sale,
enters into any negotiation or transaction for which Rule 506 (or any similar
rule then in effect) promulgated by the Securities and Exchange Commission under
the Securities Act may be available with respect to such negotiation or
transaction (including a merger, consolidation or other reorganization), Founder
will at the request of the Corporation, appoint a purchaser representative (as
such term is defined in Rule 501(h) promulgated by the Securities and Exchange
Commission under the Securities Act) reasonably acceptable to the Corporation.
If Founder appoints the purchaser representative designated by the Corporation,
the Corporation will pay the fees of such purchaser representative, but if
Founder declines to appoint the purchaser representative designated by the
Corporation, Founder will appoint another purchaser representative (reasonably
acceptable to the Corporation), and Founder will be responsible for the fees of
the purchaser representative so appointed.

     10.  Right of First Refusal.  (A) Except pursuant to Section 9 above, if at
any time Founder desires to sell for cash all or any part of Founder's Shares
pursuant to a bona fide offer from a third party (the "Proposed Transferee"),
Founder shall submit a written offer (the "Offer") to sell Founder's Shares (the
"Offered Shares") to the Purchasers on terms and conditions, including price,
not less favorable to the Purchasers than those on which Founder proposes to
sell such Offered Shares to the Proposed Transferee.  The Offer shall disclose
the identity of the Proposed Transferee, the Offered Shares proposed to be sold,
the total number of Founder's Shares owned by Founder, the terms and conditions,
including price, of the proposed sale, that the proposed buyer has been informed
of the rights and obligations provided for in this Section 10 and Section 11
below and has agreed to purchase Offered Shares in accordance with the terms of
this Agreement, and any other material facts relating to the proposed sale.  The
Offer shall further state that the Purchasers may acquire, in accordance with
the provisions of this Agreement, all but not less than all of the Offered
Shares for the price and upon the other terms and conditions, including deferred
payment (if applicable), set forth therein.

     (B) Each Purchaser shall have the absolute right to purchase that number of
Offered Shares as shall be equal to the number of Offered Shares multiplied by a
fraction, the numerator of which shall be the number of Purchasers' Shares (as
defined below) then owned by such Purchaser and the denominator of which shall
be the aggregate

                                       5
<PAGE>

number of Purchasers' Shares then owned by all of the Purchasers. For purposes
of this Section 10, all of the securities of the Corporation which a Purchaser
has acquired, or has the right to acquire from the Corporation, upon the
conversion, exercise or exchange of any of the securities of the Corporation
then owned by such Purchaser shall be deemed to be Purchasers' Shares then owned
by such Purchaser. (The amount of Offered Shares that each Purchaser is entitled
to purchase under this Section 10(B) shall be referred to as its "Pro Rata
Fraction").

     (C) The Purchasers shall have a right of oversubscription such that if any
Purchaser fails to accept the Offer as to its Pro Rata Fraction, the other
Purchasers shall, among them, have the right to purchase up to the balance of
the Offered Shares not so purchased.  Such right of oversubscription may be
exercised by a Purchaser by accepting the Offer as to more than its Pro Rata
Fraction.  If, as a result thereof, such oversubscriptions exceed the total
number of Offered Shares available in respect of such oversubscription
privilege, the oversubscribing Purchasers shall be cut back with respect to
their oversubscriptions on a pro rata basis in accordance with their respective
Pro Rata Fractions or as they may otherwise agree among themselves.  In the
event that the Purchasers in the aggregate shall not have elected in the manner
set forth below to purchase all of the Offered Shares, the Purchasers shall not
have the right to purchase any of the Offered Shares and the Founder shall have
the right to sell the Offered Shares in accordance with Section 10(E) below.

     (D) If the Purchasers, in the aggregate, desire to purchase all of the
Offered Shares, such Purchaser(s) shall communicate in writing their election to
purchase to Founder, which communication shall state the number of Offered
Shares each Purchaser desires to purchase (which shall in the aggregate be equal
to all the Offered Shares) and shall be given to Founder within thirty days of
the date the Offer was made.  Such communication shall, when taken in
conjunction with the Offer, be deemed to constitute a valid, legally binding and
enforceable agreement for the sale and purchase of such Offered Shares (subject
to the aforesaid limitations as to a Purchaser's right to purchase more than its
Pro Rata Fraction).  Sales of the Offered Shares to be sold to purchasing
Purchasers pursuant to this Section 10 shall be made at the offices of the
Corporation on the 45th day following the date the Offer was made (or if such
45th day is not a business day, then on the next succeeding business day).  Such
sales shall be effected by Founder's delivery to each purchasing Purchaser of a
certificate or certificates evidencing the Offered Shares to be purchased by it,
free and clear of any liens, claims or encumbrances of any kind (other than
pursuant to this Agreement), duly endorsed for transfer to such purchasing
Purchaser and with any requisite stock transfer stamps attached, against payment
to Founder of the purchase price therefor by such purchasing Purchaser.

     (E) If the Purchasers do not purchase all of the Offered Shares, the
Offered Shares may be sold by Founder at any time within six months after the
date the Offer was

                                       6
<PAGE>

made, subject to Section 11 below and the other provisions of this Agreement.
Any such sale shall be to the Proposed Transferee, at not less than the price
and upon other terms and conditions, if any, not more favorable to the Proposed
Transferee than those specified in the Offer. Any Offered Shares not sold within
such six-month period shall continue to be subject to the requirements of a
prior offer pursuant to this Section 10.

     11.  Co-Sale Rights.  (A) If at any time a Purchaser desires to sell all or
any part of its Common Stock or Preferred Stock ("Purchaser's Shares") pursuant
to a bona fide offer from a third party (for purposes of this Section 11, also a
"Proposed Transferee"), such Purchaser shall deliver a written notice (the
"Notice") of such proposed sale of such Purchaser's Shares (for purposes of this
Section 11, also "Offered Shares") to the other Purchaser.  The Notice shall
disclose the identity of the Proposed Transferee, the Offered Shares proposed to
be sold, the total number of Purchaser's Shares owned by such Purchaser, the
terms and conditions, including price, of the proposed sale, that the proposed
buyer has been informed of the rights and obligations provided for in this
Section 11 and has agreed to purchase Offered Shares in accordance with the
terms of this Agreement, and any other material facts relating to the proposed
sale.

     (B)  (i) If a Purchaser elects not to purchase any Offered Shares pursuant
to Section 10 above; or (ii) if upon receipt of a Notice pursuant to Section
11(A) above, such Purchaser desires to sell any of such Purchaser's Shares, then
such Purchaser shall have the right, exercisable upon written notice (the "Co-
Sale Acceptance Notice") to the selling Founder or Purchaser, as applicable,
given within thirty (30) days after the Offer or Notice, as applicable has been
delivered pursuant to Section 10 or 11(A) above, to participate in the proposed
sale of Offered Shares pursuant to the terms and conditions specified in the
Offer or Notice, as applicable, and the selling Founder or Purchaser, as
applicable, shall require the Proposed Transferee designated in the Offer or
Notice, as applicable, to purchase from such Founder or Purchaser up to the
number of whole shares of Common Stock or Preferred Stock, as applicable, equal
to the product of (i) the total number of Offered Shares to be transferred in
such proposed sale as specified in the Offer or Notice, as applicable, and (ii)
a fraction, the numerator of which (a) in the case of Offered Shares which are
Common Stock, is the number of outstanding shares of Common Stock held by such
Purchaser (including any Common Stock issuable to such Purchaser upon the
conversion or exchange of any Purchaser's Shares convertible or exchangeable
into Common Stock) or (b) in the case of Offered Shares which are Preferred
Stock, is the number of outstanding shares of Preferred Stock held by such
Purchaser, and the denominator of which (c) in the case of Offered Shares which
are Common Stock, is the total number of shares of Common Stock (on a fully-
diluted basis) then outstanding or (d) in the case of Offered Shares which are
Preferred Stock, is the total number of shares of Preferred Stock (on a fully-
diluted basis) then outstanding. The Co-Sale Acceptance Notice shall state the
number of shares such Purchaser proposes to include in such proposed sale to the
Proposed Transferee (up to the number of shares as calculated pursuant to the
immediately preceding sentence).  Any such sale by such

                                       7
<PAGE>

Purchaser shall be at the same price per share (including price and type of
consideration) received by the Proposed Transferee and otherwise on identical
terms and conditions as received by the selling Founder or Purchaser, as the
case may be, in its sale to the Proposed Transferee. In the event that the
Proposed Transferee does not purchase shares of Common Stock and/or Preferred
Stock from Purchasers who have timely delivered a Co-Sale Acceptance Notice as
required by this Section 11, then the selling Founder or Purchaser, as the case
may be, shall not be permitted to, and shall not, sell any Offered Shares to the
Proposed Transferee in the proposed sale.

     (C) If no Co-Sale Acceptance Notice is received by the selling Founder or
Purchaser, as the case may be, during the 30-day period referred to in Section
11(A) above, then such Founder or Purchaser, as the case may be, shall have the
right to sell the Offered Shares at any time within six months after the date
the Offer or Notice, as the case may be was delivered, subject to the other
provisions of this Agreement.  Any such sale shall be to the Proposed
Transferee, at not less than the price and upon other terms and conditions, if
any, not more favorable to the Proposed Transferee than those specified in the
Offer or Notice, as applicable.  Any Offered Shares not sold within such six-
month period shall continue to be subject to the requirements of Section 10 and
this Section 11.

     (D) Notwithstanding the foregoing, this Section 11 shall not apply to any
Transfer by any Purchaser or Founder of Shares:  (i) to such Purchaser's or
Founder's affiliates, members of such Purchaser's or Founder's immediate family,
family trusts or Purchasers, (ii) constituting a gift or gifts, or (iii)
constituting less than 1% of the outstanding class of Shares to be Transferred.

     12.  Termination.  The Corporation's right to repurchase Vested Shares
pursuant to Section 8 hereof, and the provisions of Sections 7, 9, 10, 11 and 13
hereof, shall terminate immediately upon the closing of a firm commitment,
underwritten public offering registered under the Securities Act, (other than a
registration relating solely to a transaction referred to in Rule 145 under the
Securities Act (or any successor rule) or to an employee benefit plan of the
Corporation), at a public offering price (prior to underwriters' discounts and
expenses) equal to or exceeding $2.50 per share of Common Stock (as adjusted for
any stock dividends, combinations or splits with respect to such shares) and in
which the aggregate proceeds to the Corporation and/or selling stockholders
(before deduction for underwriters' discounts and expenses relating to the
issuance, including without limitation fees of the Corporation's counsel) exceed
$5,000,000.

     13.  Failure to Deliver Shares.  If Founder becomes obligated to sell any
Founder's Shares to a Purchaser or the Corporation under this Agreement and
fails to deliver such Founder's Shares in accordance with the terms of this
Agreement, such Purchaser or the Corporation, as the case may be, may, at its
option, in addition to all other remedies it may have, send to Founder the
purchase price for such Founder's

                                       8
<PAGE>

Shares as is herein specified. Thereupon, the Corporation upon written notice to
Founder, (i) shall cancel on its books the certificate or certificates
representing the Founder's Shares to be sold and (ii) shall issue, in lieu
thereof, in the name of such Purchaser or the corporation, as the case may be, a
new certificate or certificates representing such Founder's Shares, and
thereupon all of Founder's rights in and to such Founder's Shares shall
terminate.

     14.  Lock-up.  If requested by the underwriters for the initial
underwritten public offering of securities of the Corporation, Founder and each
Purchaser shall agree not to sell, assign, transfer, pledge, hypothecate,
mortgage, encumber or otherwise dispose of all or any of such Founder's or
Purchaser's Shares, without the written consent of such underwriters, for a
period of not more than 180 days following the effective date of the
registration statement relating to such offering.  This Section 14 shall
expressly survive the termination of this Agreement.

     15.  No Waiver.  Any waiver of a breach of any of the terms of this
Agreement shall not operate as a waiver of any other breach of such terms or
conditions or any other terms or conditions, nor shall any failure to enforce
any provision of this Agreement operate as a waiver of such provision or any
other provision.

     16.  Successors and Assigns.  The rights, benefits and obligations of the
Corporation under this Agreement and all covenants and agreements hereunder
shall inure to the benefit of and be enforceable by or against its successors
and assigns.  Subject to the limitations set forth herein, this Agreement shall
inure to the benefit of and be binding upon the Founders' heirs, successors and
assigns.  Subject to the limitations set forth herein, neither this Agreement
nor any rights or obligations hereunder shall be assigned by any Founder.  The
rights of the Purchasers hereunder shall inure to the benefit of and be binding
upon the Purchasers respective successors and assigns.

     17.  Entire Agreement.  The Agreement (with respect to the Corporation and
the Purchasers, together with the Purchase Agreement), constitutes the entire
agreement among the parties.  This Founders Agreement may not be amended or
modified, except in writing, and signed by each of the Purchasers and Founder.

     18.  Severability.  If any provision of this Agreement or the application
thereof is held invalid or unenforceable, the invalidity or unenforceability
thereof shall not affect any other provisions or applications of this Agreement
which can be given effect without the invalid or unenforceable provision or
application.  To that end, the provisions of this Agreement are to be severable.

     19.  Governing Law.  This Agreement shall be governed by and construed in
accordance with the internal laws of the State of New York (without giving
effect to its conflicts of laws principles).

                                       9
<PAGE>

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       10
<PAGE>

     IN WITNESS WHEREOF. the Corporation has caused this Agreement to be signed
and each Founder has executed this Agreement as of the date shown below.

                                GENOMICA CORPORATION

Dated:__________, 1996          BY:  /s/ James L. Rathmann
                                   ------------------------------------
                                TITLE:_________________________________

Dated:__________, 1996          FOUNDER:  /s/ Dr. Thomas G. Marr
                                        -------------------------------
                                              Dr. Thomas G. Marr

                                PURCHASERS:

                                FALCON TECHNOLOGY PARTNERS, L.P.
                                        A Delaware limited partnership

                                BY:  /s/ James L. Rathmann
                                   ------------------------------------
                                TITLE:  General Partner

                                HARRIS & HARRIS GROUP, INC.
                                        A Delaware corporation

                                BY:  /s/ D.C.J.
                                   ------------------------------------
                                TITLE:  Executive Vice President
                                      ---------------------------------

                                       11
<PAGE>

                                  SCHEDULE 1
                                  ----------

Founder       Founders'      Vesting Schedule
-------       ---------      ----------------
              Shares
              ------

Marr          1,080,000      540,000 shares are Vested Shares immediately;
              ($1080.00)     9,000 shares become Vested Shares on the first day
                             of each calendar month commencing after the date
                             hereof.

                                       12
<PAGE>

                                   Exhibit A

                             CONSULTING AGREEMENT
                             --------------------
                               (Dr. Thomas Marr)

     AGREEMENT made as of March 22, 1996 by and between Genomica Corporation, a
Delaware corporation (the "Company''), and Dr. Thomas Marr ("Dr. Marr").

     Dr. Marr is a Senior Scientist at Cold Spring Harbor Laboratory ("Cold
Spring Harbor"), a director of the Company, the key inventor of a software
system entitled "Genome Topographer" which the Company has been organized to
exploit, and a party to a Common Stock Acquisition Agreement dated the date
hereof with the Company (the "Marr Stock Acquisition Agreement") which provides
for the acquisition by Dr. Marr of shares of common stock of the Company.

     Pursuant to a License Agreement dated the date hereof, Cold Spring Harbor
has granted the Company an exclusive license to intellectual property rights
pertaining to Genome Topographer.

     The Company, Harris & Harris Group, Inc., a New York corporation (the
"Corporate Investor"), and Falcon Technology Partners, L.P., (the "LP Investor"
and together with the Corporate Investor, the "Investors"), are parties to a
Series A Convertible Preferred Stock Purchase Agreement (the "Stock Purchase
Agreement") which provides for the purchase by the Investors of authorized but
unissued shares of the Company's Series A Preferred Stock (the "Investors Stock
Purchase").

     The Stock Purchase Agreement provides, among other things, that it is a
condition to the Investors' respective obligations to consummate the Investors
Stock Purchase that Dr. Marr enter into a Consulting Agreement with the Company
substantially in the form of this Agreement.

     The parties to the Stock Purchase Agreement and Dr. Marr desire that such
condition be satisfied, and Dr. Marr is willing to provide his services to the
Company on the terms set forth herein.

     NOW THEREFORE, in consideration of the premises, the mutual covenants and
agreements hereinafter set forth, and for other good and valuable consideration,
the receipt, adequacy and sufficiency of which are hereby acknowledged, the
parties agree as follows:

                                       1
<PAGE>

     Section 1.  Term; Consulting Fees; Independent Contractor.

            (a)  The Company hereby agrees to retain the services of Dr. Marr as
a consultant to the Company, and Dr. Marr hereby agrees to render such services
to the Company, upon the terms set forth in this Agreement, for the period
commencing on the date hereof and ending on the fifth anniversary of such date,
unless extended in accordance with the provisions of this Section 1 or earlier
terminated in accordance with the provisions of Section 6 (as so extended or
terminated, the "Term"). On each day after the third anniversary of the date
hereof, the Term shall be automatically extended for an additional day from the
then current expiration date of the Term, so that at any time the remaining Term
will consist of two years. During the, Term, the Company will pay to Dr. Marr a
base consulting fee for his services at the annual rate of $75,000, payable in
arrears in equal monthly installments.

            (b)  The Company and Dr. Marr hereby acknowledge and agree that Dr.
Marr shall perform the services provided for herein as an independent contractor
and not as an employee of the Company.  Dr. Marr agrees that he will file his
own tax returns on the basis of his status as an independent contractor for the
reporting of all income, social security, employment and other taxes due and
owing on the consideration received by him under this Agreement and that he is
responsible for the payment of such taxes.  Similarly, Dr. Marr shall not be
entitled to benefits specifically associated with employment status, such as
medical, dental and life insurance, stock (except as provided in the Marr Stock
Acquisition Agreement), and shall not be entitled to participate in any other
Company-sponsored employee benefit programs.

          Section 2.  Duties.  During the Term, Dr. Marr shall provide such
consulting and advisory services to the Company in the areas set forth on
Schedule I hereto as the Company may reasonably request (the "Consulting
Services").

          Section 3.  Expenses.  During the Term, Dr. Marr shall be entitled to
reimbursement for expenses incurred by him in connection with the performance of
his duties hereunder upon receipt of vouchers therefor in accordance with such
procedures as the Company has heretofore or may hereafter establish, or as may
be required by the Internal Revenue Service with respect to deduction of
business expenses by the Company.

          Section 4.  Termination of Service.  Notwithstanding any other
provision of this Agreement, this Agreement (and thus the Term) may be
terminated as follows:

                 (a)  Due Cause.  By the Company, at any time, for Due Cause. As
used herein, the term "Due Cause" shall mean:

                      (i)  actions or omissions of Dr. Marr constituting willful
     and material misconduct intended to enrich Dr. Marr at the expense of the
     Company;

                                       2
<PAGE>

                      (ii)   the willful and continued failure by Dr. Marr
     substantially to perform his duties hereunder (other than as a result of
     disability), which continues for a period of at least thirty (30) days
     after a demand for substantial performance is delivered to Dr. Marr by the
     Company's Board of Directors (the "Board") which specifically identifies
     the manner in which the Board believes that Dr. Marr has not substantially
     performed such duties; or

                      (iii)  the conviction of Dr. Marr of a felonious crime,
     but not a misdemeanor, involving moral turpitude.

                 (b)  Illness or Disability.  By the Company, at any time, if
Dr. Marr should be prevented by illness, accident or other disability (mental or
physical) from discharging his duties hereunder for a period of sixty (60)
consecutive days or a cumulative period of one hundred twenty (120) days in any
period of two hundred forty (240) consecutive days.

                 (c)  Voluntary by Dr. Marr For Convenience.  By Dr. Marr for
convenience, upon written notice to the Company given at least ninety (90) days
prior to the effective termination date.

                 (d)  Voluntary by Dr. Marr Upon Termination of License
Agreement.  By Dr. Marr, if the License Agreement dated the date hereof between
Cold Spring Harbor and the Company has been terminated in accordance with its
terms, upon written notice to the Company given at least ten (10) days prior to
the effective termination date.

                 (e)  Material Breach by the Company.  By Dr. Marr, at any time
by written notice to the Company, upon any material breach by the Company of the
terms hereof which continues uncured for a period of at least thirty (30) days
after a demand for substantial performance is delivered to the Board by Dr. Marr
which specifically identifies the manner in which Dr. Marr believes the Company
has materially breached this Agreement.

                 (f)  Death.  Automatically, in the event of Dr. Marr's death.

                 (g)  By The Company Without Due Cause.  By the Company, for
convenience upon written notice to Dr. Marr given at least ninety (90) days
prior to the effective termination date.

            In the event that this Agreement (and thus the Term) is terminated
pursuant to any of Sections 4(a), 4(b), 4(c) or 4(f) above, the Company's
obligation to pay further compensation to Dr. Marr hereunder shall cease
forthwith, except that Dr. Marr (or his executor in the case of his death) shall
be entitled to receive his base consulting fee through the last day of the month
in which such termination occurs (or the effective date

                                       3
<PAGE>

of termination in the case of termination pursuant to Section 4(a) or 4(c)). In
the event that this Agreement (and thus the Term) is terminated pursuant to
Section 4(d), 4(e) or 4(g) above, the Company shall continue to pay Dr. Marr his
base consulting fee for the remainder of the then current Term (as in effect
prior to such termination) at the same times as if such termination had not
occurred, provided that without limitation of its other rights or remedies, the
Company shall have the right to discontinue such consulting fee payments if (i)
Dr. Marr's representations and warranties contained in Section 6(a) prove to
have been untrue in any material respect or (ii) Dr. Marr breaches or has
breached in any material respect the Nondisclosure and Developments Agreement
(as defined herein) or the provisions of Section 6(b) or 7 hereof.

     Section 5.  Proprietary Information.  Dr. Marr has executed and delivered
to the Company a Consultant Nondisclosure and Inventions Agreement in the form
of Exhibit A hereto (the "Non-Disclosure and Developments Agreement") which is
hereby incorporated into and made a part hereof.

     Section 6.  Other Obligations.

            (a)  Dr. Marr hereby represents and warrants to, and agrees with,
the Company that (i) his performance of the Consulting Services will not (A)
result in a violation by him of any material term of any employment agreement,
non-disclosure agreement, noncompete agreement or other similar agreement with
any current or previous employer of his or (B) result in a breach of any
obligation binding on him which would prohibit the use of information obtained
from him which the Company has used or may use in the future, (ii) he is
currently employed only by Cold Spring Harbor and is not a consultant or
scientific advisor to any person or entity other than Sequana Therapeutics, Inc.
("Sequana") and (iii) on or prior to the date hereof, Dr. Marr has delivered to
the Company true and correct copies of all agreements and other documents which
set forth the terms of Dr. Marr's relationship with Sequana, and such terms will
not be altered or amended in any material respect without the prior written
consent of the Company.

            (b)  Dr. Marr undertakes that, in the performance of the Consulting
Services, Dr. Marr will not use any materials, information, technology, know-how
or documents of a former or current employer which are not generally available
to the public, unless Dr. Marr or the Company has obtained written authorization
from the current or former employer for their possession and use.

     Section 7.  Non-Solicitation.  During the Term (which, if this
Agreement is terminated other than pursuant to any of Sections 4(d), 4(e) or
4(g), shall, for purposes of this Section 7, mean the Term as in effect
immediately prior to such termination), Dr. Marr will not, directly or
indirectly, without the prior written consent of the Company, solicit or induce
any employee of the Company or any affiliate of the Company to leave the employ
of the Company or such affiliate or hire for any purpose any employee of the

                                       4
<PAGE>

Company or any affiliate of the Company or any employee who has left the
employment of the Company or any such affiliate within one year of the
termination of said employee's employment with the Company.

     Section 8.  Agreement Not to Compete.  During the term (which, if this
Agreement is terminated other than pursuant to any of Sections 4(d), 4(e) or
4(g), shall, for purposes of this Section 8, mean the Term as in effect
immediately prior to such termination), Dr. Marr will not, directly or
indirectly, engage or become interested (whether as an owner, stockholder,
partner, lender, investor, director, officer, employee, consultant or otherwise)
in any business or enterprise that is competitive with any significant part of
the business conducted by the Company or any affiliate of the Company (which for
purposes of this Section a shall be deemed to be competitive if it involves
similar research or development activities as those of the Company or any such
affiliate or similar types of products or services or proposed or anticipated
products or services as those of the Company or any such affiliate), provided
that (i) the continuation of Dr. Marr's current relationship with Sequana
(without expansion of the scope thereof or Dr. Marr's responsibilities) until
such time as the Company's business or research or development activities are
competitive with those of Sequana and (ii) ownership by Dr. Marr of not more
than 1% of the outstanding securities of any class of any corporation that are
listed on a national securities exchange or traded in the over-the-counter
market, all not be considered a breach of this Section 8.

     Section 9.  Notices.  All notices and other communications hereunder shall
be in writing and shall be deemed to have been given when hand delivered
(including by reputable overnight courier), five business days after being
mailed by first-class, registered or certified mail, postage prepaid, or when
transmitted by facsimile (with "answer-back" confirmation) as follows: (a) if to
Dr. Marr, to him at Cold Spring Harbor Laboratory, One Bungtown Road, Cold
Spring Harbor, New York 11724 (Facsimile No.: 516-367-8461); and (b) if to the
Company, c/o Falcon Technology Partners, L.P., 600 Dorset Road, Devon, PA 19333
Attention: President (Facsimile No.: ((215) 994 2222), with a copy to Harris &
Harris Group, Inc., One Rockefeller Plaza, 14 West 49th Street, New York, New
York, 10020, Attention: David C. Johnson, Jr. (Facsimile No.: ((212) 332-3601);
or to such other person(s) or address(ed) as either party shall have previously
furnished to the other party in accordance with this Section 9.

     Section 10.  Successors; Assignability; Entire Agreement.  This Agreement
shall be binding upon, and shall inure to the benefit of and be enforceable by,
the respective successors and permitted assigns of the parties hereto, provided
that this Agreement shall not be assignable (in whole or in part) by Dr. Marr.
This Agreement and the agreements referred to herein constitute the entire
agreement between the Company and Dr. Marr with respect to the matters set forth
herein and therein.

                                       5
<PAGE>

     Section 11.  Amendments; Waivers.  This Agreement may not be amended, nor
shall any waiver, change, modification, consent or discharge be effected, except
by an instrument in writing executed by or on behalf of the party against whom
enforcement of any waiver, change, modification, consent or discharge is sought.
Any failure to enforce any provision hereof shall not operate as a waiver of
such provision or of any other provision hereof.

     Section 12.  Enforcement.  Dr. Marr agrees that the Company would not be
fairly compensated by money damages for any breach of this Agreement by him and
therefore, in the event of a breach or threatened breach of this Agreement, the
Company shall be entitled to specific performance, an injunction and other
equitable relief in addition to money damages and other legal remedies. Dr. Marr
hereby waives any requirement that the Company post a bond or surety in
connection with its attempts to enforce this Agreement.

     Section 13.  Severability.  In case any one or more of the provisions of
this Agreement should be invalid, illegal or unenforceable in any respect, the
validity, legality and enforceability of the remaining provisions contained
herein shall not in any way be affected or impaired. Without limiting the
generality of the foregoing, if any provision of this Agreement is determined to
be illegal or unenforceable because of the duration thereof or the area or scope
covered, the parties hereby request any court making such determination to
reduce the duration, area and/or scope so that in its reduced form such covenant
shall be enforceable, and the parties agree that in such event all remaining
provisions shall remain in full force and effect.

     Section 14.  Counterparts.  This Agreement may be executed in two
counterparts, each of which shall be deemed an original, but which together
shall constitute one and the same instrument.

     Section 15.  Section Headings.  The headings contained in this Agreement
are for reference purposes only and shall not in any way affect the meaning or
interpretation of this Agreement.

     Section 16.  Governing Law.  This Agreement shall be governed by and
construed and enforced in accordance with the internal laws (other than the laws
governing conflict of law questions) of the State of New York.

                                       6
<PAGE>

     IN WITNESS WHEREOF, the parties have executed or caused to be executed this
Agreement as of the date first above written.

                                       GENOMICA CORPORATION

                                       By:  /s/ James L. Rathmann
                                          --------------------------------------
                                            Name:  James L. Rathmann
                                            Title:  President

                                        /s/ Dr. Thomas Marr
                                       -----------------------------------------
                                            Dr. Thomas Marr

                                       7
<PAGE>

                                                                      Schedule I
                                                                      ----------

              Areas Covered By Exclusive Consulting Relationship
              --------------------------------------------------

        1.  Genome Topographer product development
        2.  Genetic Disease Analysis tools
        3.  Locus interaction and gene expression
        4.  Gene discovery
        5.  Bioinformatic applications in the healthcare industry.

                                       8
<PAGE>

                           CONSULTANT NONDISCLOSURE
                                      AND
                             INVENTIONS AGREEMENT
                             --------------------

Name:     /s/ Thomas Marr              Engagement Date:      March 22, 1996
     ------------------------------                    -------------------------
          (Type or Print)

          In consideration of my engagement as a consultant to and the
consulting fees paid to me by Genomica Corporation, or any of its parent,
subsidiary or affiliate companies (all hereafter collectively called the
"Company") during the term of such engagement, and for other good and valuable
consideration the receipt and sufficiency of which are hereby acknowledged,
having read and understood, I hereby agree to, the following provisions for the
protection of the property rights of the Company and for the protection of the
rights of others who have entrusted the Company with confidential proprietary
information:

          1.  Disclosure to the Company.  Subject to Section 4, I agree to
disclose fully and promptly to the Company all Proprietary Information which is
developed, conceived, reduced to practice or learned by me solely or jointly
with others, at any time during the term of my engagement as a consultant to the
Company (my "Engagement").  I agree to make and maintain written records of the
aforesaid Proprietary Information and to submit promptly the same, and to make
supplemental oral disclosure, to the Company.  The term "Proprietary
Information" means all intellectual property and/or physical work product,
including without limitation, inventions, whether or not patentable and whether
or not tested or reduced to practice, discoveries, ideas, conceptions,
processes, developments, designs, business plans, trade secrets, mask works,
know-how and tangible expressions, whether or not copyrightable, computer
software, systems, programs or procedures, which (a) relates in any way to the
actual or anticipated business activities of the Company, (b) results from, or
is suggested by, work which is performed for the Company or which is funded in
whole or in part by the Company or (c) results from any use of premises,
equipment or property (tangible or intangible) owned, leased, licensed or
contracted for by the Company.

          2.  Ownership and Assignment of Assigned Intellectual Property.  I
agree to assign and hereby do assign to the Company as its exclusive property
the entire right, title and interest in and to all Proprietary Information
embraced by Paragraph 1 above which is developed, conceived, reduced to practice
or learned by me solely or jointly with others in the course of my performing
services for the Company pursuant to my Engagement, including without
limitation, all patents, patent applications and copyrights with respect thereto
(the "Assigned Intellectual Property").  I further agree to execute all papers,
and otherwise to provide all requested assistance, at the Company's expense,
during and subsequent to my Engagement, to enable the Company or its nominees to
obtain such patents, copyrights and other legal protection as it may desire in

                                      1.
<PAGE>

Genomica Corporation
Consultant Confidentiality and Inventions Agreement
Page 2

any country.  All copyrightable work ("Work") created by me in the course of my
performing services for the Company pursuant to my Engagement is intended to be
a "work made for hire" as that term is defined in Section 101 of the Copyright
Act of 1976, as amended (the "Copyright Act"), and shall be the property of the
Company, and the Company shall be the sole author of such work within the
meaning of the Copyright Act.  All such Works, as well as copies of such Works
in whatever medium fixed or embodied, shall be owned exclusively by the Company
and I expressly disclaim any interest in them. If the copyright to any such
Works shall not be the property of the Company by operation of law, I hereby
assign and will assign to the Company, without further consideration, all right,
title and interest in such Work and will assist the Company, at its expense, to
secure, maintain and defend for the benefit of the Company all copyrights,
registrations, extensions and renewals on any and all such Work, including
translations thereof in any and all countries, such Work to be and remain the
property of the Company whether copyrighted or not.

          I hereby waive all moral rights and all inalienable rights that I may
have in any Work, including without limitation, any right to identification of
authorship, any right of approval on modifications or limitation on subsequent
modifications.  To the extent that this waiver is deemed unenforceable under
applicable law, I acknowledge and agree that I will not exercise any such
inalienable right without the specific prior written consent of the Company.

          In the event that the Company is unable, after reasonable effort, to
secure my signature on letters patent, copyright or other documents relating to
any Assigned Intellectual Property, whether because of my physical or mental
incapacity or for any other reason whatsoever, I hereby irrevocably designate
and appoint the Company and its duly authorized officers and agents as my agent
and attorney-in-fact, to act for and in my behalf and stead to execute and file
any such applications(s) and to take all other lawfully permitted acts to
further the prosecution and issuance of letters patent, copyright or other
documents with the same legal force and effect as if executed by me.

          The assignment provisions of this Agreement shall not apply to
Assigned Intellectual Property which is exempt from assignment under the
applicable laws of the state governing the terms of the Consulting Agreement
between me and the Company dated as of even date herewith, to which the form of
this Agreement is attached as Exhibit A.  I agree, however, that the Company
shall have a non-exclusive, fully paid license to use for all purposes anywhere
in the world any Assigned Intellectual Property within the scope of the actual
or anticipated business of the Company but not assigned to

Consultant's name: Dr. Thomas Marr
Consultant Initial Here   ________
<PAGE>

Genomica Corporation
Consultant Confidentiality and Inventions Agreement
Page 3

the Company under this Agreement unless such a license is prohibited by statute
or by a court of last resort and final jurisdiction.

          I understand and agree that the Company shall determine, in its sole
and absolute discretion, whether an application for or registration of any
patent, copyright or other intellectual property right shall be filed on any
development assigned to the Company under this Agreement, and whether such an
application shall be prosecuted or abandoned prior to issuance or registration.

          3.  Confidentiality.  I agree that without the written permission of
the Company, I will not either during or subsequent to my Engagement, use,
publish or otherwise disclose any Confidential Information except in the course
of my duties with and in furtherance of the business of the Company and, with
respect to Confidential Information which does not constitute Assigned
Intellectual Property, except as required by my employment relationship with
Cold Spring Harbor Laboratory.  The term "Confidential Information" means any
Proprietary Information or any knowledge, information or materials about the
products, services, know-how, research and development, customers, or business
plans of the Company or any confidential information about financial matters,
marketing, pricing, compensation or any other confidential information of the
Company, its customers, or others from whom the Company has received information
under obligations of confidence.  The foregoing restrictions of this Section 3
shall not apply if (a) the proprietary or confidential information becomes
available to the public through no fault of the recipient of such disclosure,
(b) the proprietary or confidential information was known to the recipient prior
to the disclosure, and such prior knowledge is ascertainable from written
records or documents of the recipient, and the recipient is under no such
obligation of confidentiality with respect to such prior knowledge or (c) the
proprietary or confidential information is subsequently received in good faith
from a third party without breaching any obligation of confidentiality of the
third party and without breaching any such obligation imposed by the third
party.

          4.  Confidential Information of Others.  I agree not to disclose to
the Company, or to use in my work at the Company (a) any confidential
information belonging to Cold Spring Harbor Laboratory ("CSHL") or others or (b)
any prior inventions made by me which the Company is not entitled to learn of or
use. I represent that the inventions identified in the _____ pages I attach
hereto constitute all of the unpatented inventions which I have made prior to my
Engagement, which inventions shall be excluded from this Agreement.  (It is only
necessary to list the title of such

Consultant's name: Dr. Thomas Marr
Consultant Initial Here   ________
<PAGE>

Genomica Corporation
Consultant Confidentiality and Inventions Agreement
Page 4

inventions and the purpose thereof.) If there are no such unpatented inventions,
I have written my initials here: _____.

          5.  Return of Materials.  Upon the request of the Company at any time
and in the event of the termination of my Engagement, whether or not such
termination is voluntary, I will deliver promptly to my supervisor at the
Company, or to the Board of Directors of the Company, all documents which relate
to business activities of the Company, and all materials and things which belong
to the Company or have been given to me by the Company or others during the
course of my engagement as a consultant thereto.

          6.  Prior Agreements; Consultant Obligations Subject to CSHL
Inventions Agreement.  I represent that I have attached hereto a copy of the
Inventions Agreement between CSHL and me, as currently in effect (the "CSHL
Inventions Agreement"), and any other agreement (such as a prior employment
agreement) which affects my ability to comply with the terms of this Agreement.
It is expressly understood and agreed that my obligations hereunder shall be
subject to the provisions of the CSHL Inventions Agreement.

          7.  Enforcement.  I agree that the Company would not be fairly
compensated by money damages for any breach of this Agreement by me and
therefore, in the event of a breach or threatened breach of this Agreement, the
Company shall be entitled to specific performance, an injunction and other
equitable relief in addition to money damages and other legal remedies.  I
hereby waive any requirement that the Company post a bond or surety in
connection with its enforcement of this Agreement.

Consultant's name: Dr. Thomas Marr
Consultant Initial Here   ________
<PAGE>

Genomica Corporation
Consultant Confidentiality and Inventions Agreement
Page 5

          8.  Miscellaneous.   This Agreement shall be binding on my executors,
administrators, heirs, legal representatives or assigns, and may not be modified
except in writing with the approval of a duly authorized officer of the Company.
If any provision of this Agreement is determined to be illegal or unenforceable,
because of the duration thereof or the area or scope covered, I hereby request
any court making such determination to reduce the duration, area and/or scope so
that in its reduced form such covenant shall be enforceable and I agree that in
such event all remaining provisions shall remain in full force and effect.  This
Agreement shall be governed and construed in accordance with the internal laws
(other than the laws governing conflict of law questions) of the State of New
York.  This agreement and the Consulting Agreement referred to herein set the
entire agreement between the Company and me with respect to the matters set
forth herein and therein.

WITNESS:                                     CONSULTANT:

                                                        /s/ Thomas Marr
___________________________________          -----------------------------------

Date:______________________________          Date:            3/19/96
                                                  ------------------------------

                                             Social Security No.   ###-##-####
                                                                ----------------

WITNESS:                                     GENOMICA CORPORATION (for
                                             purposes of section 6 only)

                                             By:  /s/ James L. Rathmann
___________________________________             --------------------------------
                                                Name:  James L. Rathmann
Date:______________________________             Title:  President

                                             Date:           3/25/96
                                                  ------------------------------
<PAGE>

                             GENOMICA CORPORATION
                              FOUNDERS AGREEMENT

     THIS AGREEMENT is made as of the  22 th day of March, 1996, by and among
Genomica Corporation, a Delaware corporation, (the "Corporation"), Jacqueline
Salit ("Founder") and the persons (the "Purchasers") named in Schedule I to a
certain Series A Convertible Preferred Stock Purchase Agreement of the
Corporation dated the date hereof (the "Purchase Agreement").

                                   RECITALS
                                   --------

     The Corporation is engaged in the highly competitive business of
researching, developing, manufacturing and marketing computer software for the
biotechnology industry on an international basis.  Founder and the Corporation
recognize and affirm that success or failure in this highly technical and highly
competitive business is dependent on the ability of the Corporation to (1)
develop and protect proprietary technology which will give the Corporation a
competitive advantage in the marketplace; (2) incorporate this technology into
products which themselves will or may become proprietary; and (3) develop and
utilize processes which may be proprietary to accomplish (1) and (2) above.

     In order to achieve the above objectives, the Corporation has expended and
will continue to expend substantial time, effort and financial resources.  These
activities include research, the attraction and training of key employees, and
establishing relationships with necessary resources outside the Corporation.  If
information regarding the Corporation's research, processes or products were to
fall into the hands of a competitor of the Corporation, it could be used in a
manner which would cause serious and irreparable financial and business damage
to the Corporation.  For this reason, all information related to the
Corporation's technology, research, products, and business strategies is
considered to be confidential information which is proprietary to the
Corporation.

     In addition, the Purchasers intend to invest in the Corporation pursuant to
the Purchase Agreement based on the foregoing assumptions and such investment is
contingent upon the execution and delivery of this Agreement by the Corporation
and Founder.

                                   AGREEMENT
                                   ---------

     NOW, THEREFORE, in consideration of the above representations and
understandings, and the promises and mutual agreements set forth below, the
parties agree, effective on the date of the Agreement, to the following terms
and conditions:
<PAGE>

     1.  Services.  Founder agrees to serve the Corporation as reasonably
directed by its Board of Directors or its designee, consistent with the scope of
expertise and other employment obligations of Founder.  Such services may
include participation in the Corporation as a director, officer, scientific
advisor, consultant, contractor and/or, with the agreement of Founder, an
employee.  In all such cases, the terms and conditions of this Agreement will
continue to be binding.

     2.  Founder's Stock.  Founder has purchased from the Corporation an
aggregate of 30,000 shares of Common Stock (the "Shares") at a per-share
purchase price of $.001 (the "Original Purchase Price") as more specifically set
forth on Schedule 1 hereto.  Founder's Shares shall be subject to a number of
restrictions as set forth in this Agreement.  Certain of the restrictions with
respect to Founder's Shares may terminate under various conditions pursuant
hereto in consideration for Founder's service to the Corporation as described
herein.

     3.  [INTENTIONALLY OMITTED]

     4.  Disclosure and Assignment of Technology to Corporation.  Concurrently
with the execution of this Agreement, Founder is executing and delivering a
Nondisclosure Agreement substantially in the form set forth as Exhibit A hereto
(the "Nondisclosure Agreement").

     5.  [INTENTIONALLY OMITTED]

     6.  Remedies in the Event of Breach.  The Corporation, the Purchasers and
Founder understand and agree that any breach or threatened breach by the
Corporation or Founder of any of the provisions hereof cannot be remedied solely
by the recovery of damages, and in the event of any such breach or threatened
breach, the Corporation or the Purchasers, as the case may be, shall be entitled
to injunctive relief, restraining Founder, and any business, firm, corporation,
individual or other entity participating in such breach or attempted breach from
engaging in any activity which would constitute a breach.  The Corporation, the
Purchasers and Founder further agree that any dispute arising under the terms of
this Agreement shall be decided in accordance with the rules then in effect of
the American Arbitration Association, and any arbitration award may be entered
in a court of competent jurisdiction and enforced as a judgment thereof.
Nothing herein, however, shall be construed as (i) prohibiting the Corporation,
the Purchasers or Founder from pursuing, in conjunction with an injunction or
otherwise, any other remedies available in equity or at law for any such breach
or threatened breach, including the recovery of damages; or (ii) limiting the
Corporation's remedy against Founder as set forth in Section 13 below.

     7.  Transferability.  The Corporation and Founder agree (i) that Unvested
Shares (as defined below) may not be sold, pledged or otherwise transferred
("Transferred") without the consent of the Board of Directors in its sole
discretion

                                       2
<PAGE>

(except pursuant to Section 9 below); and (ii) Vested Shares (as defined below)
may be Transferred only in accordance with the provisions set forth herein and
only if the transferee of such Vested Shares agrees in writing to be bound by
the provisions of Sections 9, 10, 11, 13 and 14 hereof. Any Founder's Shares
Transferred not in accordance with the preceding sentence shall be void, ab
initio.

     8.  Founder's Stock.  Founder's Shares shall be affected as follows:

     (A) In the event (i) Founder dies; (ii) of a breach by Founder of any of
the terms of the Consulting Agreement or the Common Stock Acquisition Agreement
by which Founder purchased the Founder's Shares (any such case, a
"Discontinuation Event"), certain of Founder's Shares, defined below as
"Unvested Shares," shall be repurchased and paid for in full by the Corporation
at the Original Purchase Price within 30 days of such Discontinuation Event.
Unvested Shares shall be those Founder's Shares which have not yet vested
according to the schedule set forth in Schedule 1 hereto.  Notwithstanding the
preceding sentence, in the event the Corporation's Board of Directors approves a
sale or merger (other than a merger with or into a wholly-owned subsidiary of
the Corporation or a merger in which the Corporation is the surviving entity) of
the Corporation or an initial public offering of the Corporation's stock (any of
which events is defined herein as a "Triggering Transaction"), Founder will be
notified of such Board action.  Any of Founder's then Unvested Shares will
become Vested Shares (as defined below) simultaneously with the consummation of
the Triggering Transaction.  Upon the occurrence of a Discontinuation Event, all
of Founder's Unvested Shares shall forever remain Unvested Shares.

     (B) Upon the occurrence of a Discontinuation Event, Founder's Shares which
are vested pursuant to Schedule 1 hereto ("Vested Shares") may be repurchased by
the Corporation, solely at the option of the Corporation (the "Corporation
Option"), at Fair Market Value (as defined below).  The Corporation agrees to
give Founder (or his estate) notice of its intent to exercise the Corporation
Option within ninety (90) days of the date of such Discontinuation Event and to
pay for those shares for which it exercises such Corporation Option as follows:
3/24ths of the total price within 90 days of the date of the Discontinuation
Event, with the balance to be paid in equal monthly installments over the next
succeeding twenty-one months.

     (C) Termination For Cause.  Prior to the Corporation's initial public
offering, in the event of a Discontinuation Event with respect to Founder
occurring as a result of an event set forth in clause (ii) of Section 8(A)
above, then with respect to any of Founder's Shares not repurchased by the
Corporation pursuant to Sections 8(A) or 8(B) above, Founder shall, in all
matters put forth to a vote of the holders of Common Stock (i) cause such
Founder's Shares to be represented at any meeting of the stockholders of the
Corporation and (ii) vote such shares in the same proportion and in the same
manner as all other Common Stock is voted.

                                       3
<PAGE>

     (D) Fair Market Value.  For the purposes of Section 8(B), Fair Market Value
shall be that value as determined in good faith by the Board of Directors.  Any
Founder (or her estate) may request an appraisal by written notice of objection
delivered not later than fifteen (15) days after receipt of such Fair Market
Value determination by the Board of Directors.  If an appraisal is demanded, the
Corporation shall select an appraiser reasonably acceptable to Founder (or her
estate) to appraise Founder's Vested Shares, and the repurchase price payable
upon the Corporation's exercise of the Corporation Option shall be the higher of
such appraisal and such Fair Market Value determination by the Board of
Directors.  If such appraisal results in a valuation more than 10% higher than
the Fair Market Value determination by the Board of Directors, then all expenses
of such appraisal shall be paid by the Corporation; otherwise, all expenses of
such appraisal shall be paid by Founder (or her estate).

     9.  Approved Sale of Corporation.  (A) If the Corporation's Board of
Directors has adopted a resolution of the Board of Directors approving the sale
of the Corporation to any person (such person, the "Acquiring Entity"), whether
by merger, consolidation, sale of all or substantially all of the Corporation's
assets or sale of all of the outstanding capital stock (such sale, an "Approved
Sale"), Founder and each Purchaser will consent to, vote for and raise no
objections against the Approved Sale, and if the Approved Sale is structured as
a sale of stock, Founder and each Purchaser hereby agrees to sell all of their
respective Shares (and all rights thereto) on the terms and conditions approved
by the Board of Directors, provided that each holder of Common Stock receives in
the Approved Sale the same amount and type of consideration for its interest in
the Corporation as is received by the holders of the Series A Convertible
Preferred Stock, (the "Preferred Stock"), assuming such holders had converted
their respective shares of Preferred Stock into Common Stock.  Founder and each
Purchaser will take all actions reasonably required to facilitate and consummate
an Approved Sale of the Corporation.

     (B) The Corporation shall give written notice (a "Sale Notice") of any such
Approved Sale to Founder and Purchasers.  A Sale Notice shall contain  (i) the
name and address of the prospective Acquiring Entity; (ii) the purchase price
and other material terms and conditions of the Approved Sale; (iii) the date on
which the Approved Sale is intended to be consummated; (iv) the date on which
the Corporation's Board of Directors approved the Approved Sale and (v) the
Founder's and Purchaser's Shares proposed to be sold.  Upon receipt of a Sale
Notice, Founder and each Purchaser shall be required to consent to such Approved
Sale and to sell its Founder's or Purchaser's Shares, as the case may be, to the
Acquiring Entity designated therein within 30 days of receipt thereof or such
later date as may be specified in the Sale Notice.  No Purchaser or Founder
shall be required to make any representations and warranties other than
representations and warranties concerning its ownership of such Founder's or
Purchaser's Shares, the absence of any liens or encumbrances thereon and its
authority to sell such Shares; and provided further that, if the terms of such
                                   ---------------------
Approved Sale provide for the escrow of any amount of proceeds resulting from an
Approved Sale or to accept indebtedness or other securities

                                       4
<PAGE>

subject to indemnification or other rights of offset, then Founder and
Purchasers shall be required to escrow a pro rata amount of its proceeds from
such Approved Sale and/or to accept such indebtedness or other securities.

     (C) If the Corporation or Founder, in connection with any Approved Sale,
enters into any negotiation or transaction for which Rule 506 (or any similar
rule then in effect) promulgated by the Securities and Exchange Commission under
the Securities Act may be available with respect to such negotiation or
transaction (including a merger, consolidation or other reorganization), Founder
will at the request of the Corporation, appoint a purchaser representative (as
such term is defined in Rule 501(h) promulgated by the Securities and Exchange
Commission under the Securities Act) reasonably acceptable to the Corporation.
If Founder appoints the purchaser representative designated by the Corporation,
the Corporation will pay the fees of such purchaser representative, but if
Founder declines to appoint the purchaser representative designated by the
Corporation, Founder will appoint another purchaser representative (reasonably
acceptable to the Corporation), and Founder will be responsible for the fees of
the purchaser representative so appointed.

     10.  Right of First Refusal.  (A) Except pursuant to Section 9 above, if at
any time Founder desires to sell for cash all or any part of Founder's Shares
pursuant to a bona fide offer from a third party (the "Proposed Transferee"),
Founder shall submit a written offer (the "Offer") to sell Founder's Shares (the
"Offered Shares") to the Purchasers on terms and conditions, including price,
not less favorable to the Purchasers than those on which Founder proposes to
sell such Offered Shares to the Proposed Transferee.  The Offer shall disclose
the identity of the Proposed Transferee, the Offered Shares proposed to be sold,
the total number of Founder's Shares owned by Founder, the terms and conditions,
including price, of the proposed sale, that the proposed buyer has been informed
of the rights and obligations provided for in this Section 10 and Section 11
below and has agreed to purchase Offered Shares in accordance with the terms of
this Agreement, and any other material facts relating to the proposed sale.  The
Offer shall further state that the Purchasers may acquire, in accordance with
the provisions of this Agreement, all but not less than all of the Offered
Shares for the price and upon the other terms and conditions, including deferred
payment (if applicable), set forth therein.

     (B) Each Purchaser shall have the absolute right to purchase that number of
Offered Shares as shall be equal to the number of Offered Shares multiplied by a
fraction, the numerator of which shall be the number of Purchasers' Shares (as
defined below) then owned by such Purchaser and the denominator of which shall
be the aggregate number of Purchasers' Shares then owned by all of the
Purchasers.  For purposes of this Section 10, all of the securities of the
Corporation which a Purchaser has acquired, or has the right to acquire from the
Corporation, upon the conversion, exercise or exchange of any of the securities
of the Corporation then owned by such Purchaser shall be deemed to be
Purchasers' Shares then owned by such Purchaser.  (The amount of Offered Shares

                                       5
<PAGE>

that each Purchaser is entitled to purchase under this Section 10(B) shall be
referred to as its "Pro Rata Fraction").

     (C) The Purchasers shall have a right of oversubscription such that if any
Purchaser fails to accept the Offer as to its Pro Rata Fraction, the other
Purchasers shall, among them, have the right to purchase up to the balance of
the Offered Shares not so purchased.  Such right of oversubscription may be
exercised by a Purchaser by accepting the Offer as to more than its Pro Rata
Fraction.  If, as a result thereof, such oversubscriptions exceed the total
number of Offered Shares available in respect of such oversubscription
privilege, the oversubscribing Purchasers shall be cut back with respect to
their oversubscriptions on a pro rata basis in accordance with their respective
Pro Rata Fractions or as they may otherwise agree among themselves.  In the
event that the Purchasers in the aggregate shall not have elected in the manner
set forth below to purchase all of the Offered Shares, the Purchasers shall not
have the right to purchase any of the Offered Shares and the Founder shall have
the right to sell the Offered Shares in accordance with Section 10(E) below.

     (D) If the Purchasers, in the aggregate, desire to purchase all of the
Offered Shares, such Purchaser(s) shall communicate in writing their election to
purchase to Founder, which communication shall state the number of Offered
Shares each Purchaser desires to purchase (which shall in the aggregate be equal
to all the Offered Shares) and shall be given to Founder within thirty days of
the date the Offer was made.  Such communication shall, when taken in
conjunction with the Offer, be deemed to constitute a valid, legally binding and
enforceable agreement for the sale and purchase of such Offered Shares (subject
to the aforesaid limitations as to a Purchaser's right to purchase more than its
Pro Rata Fraction).  Sales of the Offered Shares to be sold to purchasing
Purchasers pursuant to this Section 10 shall be made at the offices of the
Corporation on the 45th day following the date the Offer was made (or if such
45th day is not a business day, then on the next succeeding business day).  Such
sales shall be effected by Founder's delivery to each purchasing Purchaser of a
certificate or certificates evidencing the Offered Shares to be purchased by it,
free and clear of any liens, claims or encumbrances of any kind (other than
pursuant to this Agreement), duly endorsed for transfer to such purchasing
Purchaser and with any requisite stock transfer stamps attached, against payment
to Founder of the purchase price therefor by such purchasing Purchaser.

     (E) If the Purchasers do not purchase all of the Offered Shares, the
Offered Shares may be sold by Founder at any time within six months after the
date the Offer was made, subject to Section 11 below and the other provisions of
this Agreement.  Any such sale shall be to the Proposed Transferee, at not less
than the price and upon other terms and conditions, if any, not more favorable
to the Proposed Transferee than those specified in the Offer.  Any Offered
Shares not sold within such six-month period shall continue to be subject to the
requirements of a prior offer pursuant to this Section 10.

                                       6
<PAGE>

     11.  Co-Sale Rights.  (A) If at any time a Purchaser desires to sell all or
any part of its Common Stock or Preferred Stock ("Purchaser's Shares") pursuant
to a bona fide offer from a third party (for purposes of this Section 11, also a
"Proposed Transferee"), such Purchaser shall deliver a written notice (the
"Notice") of such proposed sale of such Purchaser's Shares (for purposes of this
Section 11, also "Offered Shares") to the other Purchaser.  The Notice shall
disclose the identity of the Proposed Transferee, the Offered Shares proposed to
be sold, the total number of Purchaser's Shares owned by such Purchaser, the
terms and conditions, including price, of the proposed sale, that the proposed
buyer has been informed of the rights and obligations provided for in this
Section 11 and has agreed to purchase Offered Shares in accordance with the
terms of this Agreement, and any other material facts relating to the proposed
sale.

     (B) (i) If a Purchaser elects not to purchase any Offered Shares pursuant
to Section 10 above; or (ii) if upon receipt of a Notice pursuant to Section
11(A) above, such Purchaser desires to sell any of such Purchaser's Shares, then
such Purchaser shall have the right, exercisable upon written notice (the "Co-
Sale Acceptance Notice") to the selling Founder or Purchaser, as applicable,
given within thirty (30) days after the Offer or Notice, as applicable has been
delivered pursuant to Section 10 or 11(A) above, to participate in the proposed
sale of Offered Shares pursuant to the terms and conditions specified in the
Offer or Notice, as applicable, and the selling Founder or Purchaser, as
applicable, shall require the Proposed Transferee designated in the Offer or
Notice, as applicable, to purchase from such Founder or Purchaser up to the
number of whole shares of Common Stock or Preferred Stock, as applicable, equal
to the product of (i) the total number of Offered Shares to be transferred in
such proposed sale as specified in the Offer or Notice, as applicable, and (ii)
a fraction, the numerator of which (a) in the case of Offered Shares which are
Common Stock, is the number of outstanding shares of Common Stock held by such
Purchaser (including any Common Stock issuable to such Purchaser upon the
conversion or exchange of any Purchaser's Shares convertible or exchangeable
into Common Stock) or (b) in the case of Offered Shares which are Preferred
Stock, is the number of outstanding shares of Preferred Stock held by such
Purchaser, and the denominator of which (c) in the case of Offered Shares which
are Common Stock, is the total number of shares of Common Stock (on a fully-
diluted basis) then outstanding or (d) in the case of Offered Shares which are
Preferred Stock, is the total number of shares of Preferred Stock (on a fully-
diluted basis) then outstanding . The Co-Sale Acceptance Notice shall state the
number of shares such Purchaser proposes to include in such proposed sale to the
Proposed Transferee (up to the number of shares as calculated pursuant to the
immediately preceding sentence).  Any such sale by such Purchaser shall be at
the same price per share (including price and type of consideration) received by
the Proposed Transferee and otherwise on identical terms and conditions as
received by the selling Founder or Purchaser, as the case may be, in its sale to
the Proposed Transferee.  In the event that the Proposed Transferee does not
purchase shares of Common Stock and/or Preferred Stock from Purchasers who have
timely delivered a Co-Sale Acceptance Notice as required by this Section 11,
then the selling Founder or

                                       7
<PAGE>

Purchaser, as the case may be, shall not be permitted to, and shall not, sell
any Offered Shares to the Proposed Transferee in the proposed sale.

     (C) If no Co-Sale Acceptance Notice is received by the selling Founder or
Purchaser, as the case may be, during the 30-day period referred to in Section
11(A) above, then such Founder or Purchaser, as the case may be, shall have the
right to sell the Offered Shares at any time within six months after the date
the Offer or Notice, as the case may be was delivered, subject to the other
provisions of this Agreement.  Any such sale shall be to the Proposed
Transferee, at not less than the price and upon other terms and conditions, if
any, not more favorable to the Proposed Transferee than those specified in the
Offer or Notice, as applicable.  Any Offered Shares not sold within such six-
month period shall continue to be subject to the requirements of Section 10 and
this Section 11.

     (D) Notwithstanding the foregoing, this Section 11 shall not apply to any
Transfer by any Purchaser or Founder of Shares:  (i) to such Purchaser's or
Founder's affiliates, members of such Purchaser's or Founder's immediate family,
family trusts or Purchasers, (ii) constituting a gift or gifts, or (iii)
constituting less than 1% of the outstanding class of Shares to be Transferred.

     12.  Termination.  The Corporation's right to repurchase Vested Shares
pursuant to Section 8 hereof, and the provisions of Sections 7, 9, 10, 11 and 13
hereof, shall terminate immediately upon the closing of a firm commitment,
underwritten public offering registered under the Securities Act, (other than a
registration relating solely to a transaction referred to in Rule 145 under the
Securities Act (or any successor rule) or to an employee benefit plan of the
Corporation), at a public offering price (prior to underwriters' discounts and
expenses) equal to or exceeding $2.50 per share of Common Stock (as adjusted for
any stock dividends, combinations or splits with respect to such shares) and in
which the aggregate proceeds to the Corporation and/or selling stockholders
(before deduction for underwriters' discounts and expenses relating to the
issuance, including without limitation fees of the Corporation's counsel) exceed
$5,000,000.

     13.  Failure to Deliver Shares.  If Founder becomes obligated to sell any
Founder's Shares to a Purchaser or the Corporation under this Agreement and
fails to deliver such Founder's Shares in accordance with the terms of this
Agreement, such Purchaser or the Corporation, as the case may be, may, at its
option, in addition to all other remedies it may have, send to Founder the
purchase price for such Founder's Shares as is herein specified.  Thereupon, the
Corporation upon written notice to Founder, (i) shall cancel on its books the
certificate or certificates representing the Founder's Shares to be sold and
(ii) shall issue, in lieu thereof, in the name of such Purchaser or the
corporation, as the case may be, a new certificate or certificates representing
such Founder's Shares, and thereupon all of Founder's rights in and to such
Founder's Shares shall terminate.

                                       8
<PAGE>

     14.  Lock-up.  If requested by the underwriters for the initial
underwritten public offering of securities of the Corporation, Founder and each
Purchaser shall agree not to sell, assign, transfer, pledge, hypothecate,
mortgage, encumber or otherwise dispose of all or any of such Founder's or
Purchaser's Shares, without the written consent of such underwriters, for a
period of not more than 180 days following the effective date of the
registration statement relating to such offering.  This Section 14 shall
expressly survive the termination of this Agreement.

     15.  No Waiver.  Any waiver of a breach of any of the terms of this
Agreement shall not operate as a waiver of any other breach of such terms or
conditions or any other terms or conditions, nor shall any failure to enforce
any provision of this Agreement operate as a waiver of such provision or any
other provision.

     16.  Successors and Assigns.  The rights, benefits and obligations of the
Corporation under this Agreement and all covenants and agreements hereunder
shall inure to the benefit of and be enforceable by or against its successors
and assigns.  Subject to the limitations set forth herein, this Agreement shall
inure to the benefit of and be binding upon the Founders' heirs, successors and
assigns.  Subject to the limitations set forth herein, neither this Agreement
nor any rights or obligations hereunder shall be assigned by any Founder.  The
rights of the Purchasers hereunder shall inure to the benefit of and be binding
upon the Purchasers respective successors and assigns.

     17.  Entire Agreement.  The Agreement (with respect to the Corporation and
the Purchasers, together with the Purchase Agreement), constitutes the entire
agreement among the parties.  This Founders Agreement may not be amended or
modified, except in writing, and signed by each of the Purchasers and Founder.

     18.  Severability.  If any provision of this Agreement or the application
thereof is held invalid or unenforceable, the invalidity or unenforceability
thereof shall not affect any other provisions or applications of this Agreement
which can be given effect without the invalid or unenforceable provision or
application.  To that end, the provisions of this Agreement are to be severable.

     19.  Governing Law.  This Agreement shall be governed by and construed in
accordance with the internal laws of the State of New York (without giving
effect to its conflicts of laws principles).

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       9
<PAGE>

     IN WITNESS WHEREOF. the Corporation has caused this Agreement to be signed
and each Founder has executed this Agreement as of the date shown below.

                                GENOMICA CORPORATION

Dated: ???, 22  , 1996          BY:  /s/ James L. Rathmann
      ----------                   ------------------------------------
                                TITLE:_________________________________

Dated: 3/21/96  , 1996          FOUNDER:  /s/ Jacqueline Salit
       ---------                        -------------------------------
                                              Jacqueline Salit

                                PURCHASERS:

                                FALCON TECHNOLOGY PARTNERS, L.P.
                                        A Delaware limited partnership

                                BY:  /s/ James L. Rathmann
                                   ------------------------------------
                                TITLE:  General Partner

                                HARRIS & HARRIS GROUP, INC.
                                        A NY corporation

                                BY:  /s/ D.C.J.
                                   ------------------------------------
                                TITLE:  Executive Vice President
                                      ---------------------------------

                                       10
<PAGE>

                                  SCHEDULE 1
                                  ----------

Founder         Founders'       Vesting Schedule
-------         ---------       ----------------
                Shares
                ------
Salit           30,000          15,000 shares become Vested Shares on the date
                ($30.00)        hereof and the remaining shares become Vested
                                Shares on the first anniversary of the date
                                hereof; provided however, that notwithstanding
                                the above provisions, if Salit leaves the employ
                                of Cold Spring Harbor for any reason except to
                                become an employee of the Company, all shares
                                which have not yet become Vested Shares will
                                always remain Unvested Shares.

                                       11
<PAGE>

                                   Exhibit A

                           CONFIDENTIALITY AGREEMENT
                           -------------------------

Name:       Jacqueline Salit            Employment Date:         9/9/91
     ------------------------------                     ------------------------
             (Type or Print)

          In consideration of (i) Genomica Corporation (the "Company") entering
into certain agreements and arrangements with my employer, Cold Spring Harbor
Laboratory ("Cold Spring Harbor"), whereby the Company will, among other things,
sponsor certain research activities in which I may be involved, and (ii) the
Company's issuance and sale to me of shares of its common stock pursuant to a
Common Stock Acquisition Agreement between the Company and me, and for other
good and valuable consideration, the receipt and sufficiency of which are by
acknowledged, I understand and agree to the following provisions for the
protection of the confidential information of the Company.

          1.        Confidentiality.  I agree that without the written
permission of the Company, I will not knowingly use, publish or otherwise
disclose any Confidential Information.  The term "Confidential Information"
means any Proprietary Information or any knowledge, information or materials
about the products, services, know-how, research and development, customers, or
business plans of the Company or any confidential information about financial
matters, marketing, pricing, compensation or any other confidential information
of the Company, its customers, or others from whom the Company has received
information under obligations of confidence which have been communicated to me
in writing.  The term "Proprietary Information" means all intellectual and/or
physical work product, including without limitation, inventions, whether or not
patentable and whether or not tested or reduced to practice, discoveries, ideas,
conceptions, processes, developments, designs, business plans, trade secrets,
mask works, know-how and tangible expressions, whether or not copyrightable,
computer software, systems, programs or procedures, which (a) relates to the
actual or anticipated business activities of the Company, (b) results from work
which is performed for the Company or which is funded in whole or in part by the
Company or (c) results from any use of premises, equipment or property (tangible
or intangible) owned, leased, licensed or contracted for by the Company.
Notwithstanding the foregoing provisions of this paragraph 1 to the contrary,
"Confidential information" shall not include any information which (i) has been
made available to the general public of information which subsequently comes in
the public domain through no fault or omissions by me, (ii) is subsequently
disclosed by a third party which has the bona fide right to make such
disclosure, (iii) is required to be disclosed by law or a governmental agency
and (iv) is already generally known by personas in the computer software
industry or developed by
<PAGE>

Genomica Corporation
Confidentiality Agreement
Page 2

me independent of my work with the Company or Cold Spring Harbor without use of
any Confidential Information.

          2.  Confidential Information of Others.  I agree not to knowingly
disclose to the Company (a) any confidential information belonging to others or
(b) any prior inventions made by me which the Company is not entitled to learn
of or use.

          3.  Return of Materials.  Upon the written request of the Company at
any time, I will deliver promptly to the Company all documents, materials and
things (if any) in my possession which belong to the Company or have been given
to me by the Company.

          4.  Prior Agreements.  I represent that I have attached hereto a copy
of any agreement (such as a prior employment agreement) which affects my ability
to comply with the terms of this Agreement. If there is no such agreement, I
have written my initials here:  JS
                              ------

          5.  Enforcement.  I agree that the Company would not be fairly
compensated by money damages for any breach of this Agreement by me and
therefore, in the event of a breach or threatened breach of this Agreement, the
Company shall be entitled to specific performance, an injunction and other
equitable relief in addition to money damages and other legal remedies.

          6.  Miscellaneous.   This Agreement shall be binding on my executors,
administrators, heirs, legal representatives or assigns, and may not be modified
except in writing with the approval of a duly authorized officer of the Company.
If any provision of this Agreement is determined to be illegal or unenforceable,
because of the duration thereof or the area or scope covered, I hereby request
any court making such determination to reduce the duration, area and/or scope so
that in its reduced form such covenant shall be enforceable and I agree that in
such event all remaining provisions shall remain in full force and effect. This
Agreement shall be governed and construed in accordance with the internal laws
of the State of New York. This document sets forth the entire agreement between
the Company and me with respect to the matters set forth herein.

WITNESS:

         /s/ Steven Cozza                            /s/ Jacqueline Salit
-----------------------------------          -----------------------------------
          Steven Cozza                                  Jacqueline Salit

Date:        3/21/96                         Date:         3/21/96
     ------------------------------               ------------------------------

                                             Social Security No.   ###-##-####
                                                                ----------------<PAGE>

                                                                    EXHIBIT 10.4

                               VOTING AGREEMENT

     AGREEMENT dated as of March 22, 1996, by and among Genomica Corporation, a
Delaware corporation (the "Company"), the persons listed as Purchasers in
Schedule I to a certain Series A Convertible Preferred Stock Purchase Agreement
of the Company dated as of the date hereof (the "Purchase Agreement")
(collectively, the "Purchasers" and individually a "Purchaser") and the persons
listed as Stockholders in the signature pages hereto (collectively, the
"Stockholders" and individually, a "Stockholder").

     WHEREAS, on the date hereof, the Purchasers are purchasing from the Company
shares of its Series A Preferred Stock (the "Series A Preferred") pursuant to
the terms of the Purchase Agreement, a copy of which is attached hereto as
Exhibit A; and

     WHEREAS, the Purchasers and the Stockholders wish to make certain
provisions for the voting of their Shares (as defined below); and

     WHEREAS, the purchases by the Purchasers will benefit the Company; and

     WHEREAS, it is a condition to the obligations of the Purchasers under the
Purchase Agreement that this Agreement be executed by the parties hereto, and
the parties are willing to execute this Agreement and to be bound by the
provisions hereof;

     NOW, THEREFORE, in consideration of the premises, the agreements set forth
below, and the parties' desire to further the interests of the Company and its
present and future stockholders, the parties agree as follows:

     1.  Definition. As used in this Agreement, the term "Shares" means all
shares of equity securities of the Company (i) now or hereafter owned (either
beneficially or of record) by a Stockholder or a Purchaser, and (ii) which a
Stockholder or a Purchaser does not own (either beneficially or of record) but
as to which it now or hereafter has the right to exercise voting control.

     2.  Designation of Nominees. (a) Each of Falcon Technology Partners, L.P.
("Falcon") and Harris & Harris Group, Inc. ("Harris") (together, the "Nominating
Purchasers" and individually, a "Nominating Purchaser") so long as they own any
shares shall have the right to designate a nominee (together, the "Nominees" and
individually, a "Nominee") for election as one of the directors of the Company
who shall be elected solely by the holders of the Series A Preferred, voting
separately as a series (the "Series A Directors") pursuant to the Company's
Certificate of Incorporation. Falcon and Harris together shall have the right to
designate a third Nominee who shall be elected as Series A Director. At least 10
days prior to any meeting (or written action in lieu of a meeting) of
stockholders of the Company at or by which directors are to be elected by the
holders of Series A Preferred, voting separately as a series, each Nominating
Purchaser shall
<PAGE>

notify the other Purchaser in writing of the Nominee designated by such
Nominating Purchaser for election as a director. In the absence of any such
notification, it shall be presumed that the Nominating Purchaser's then
incumbent Nominee has been redesignated as its Nominee. The initial Nominees of
Falcon and Harris are James L. Rathmann, Charles Hams and David C. Johnson, Jr.,
respectively.

         (b)  One of the directors of the Company (the "Common Director") is
elected solely by the holders of Common Stock pursuant to the Company's
Certificate of Incorporation. The holders of a majority in interest of the then
outstanding Common Stock, excluding for this purpose any shares of Common Stock
then owned, or as to which the power to vote is held, by any Purchaser and also
excluding Cold Spring Harbor Laboratory ("CSH") if CSH has the right to
designate a Nominee for election as a director pursuant to Section 2(c) below
(the "Designating Common Holders"), shall have the right to designate the
nominee for election as a director solely by the holders of Common Stock. At
least 10 days prior to any meeting (or written action in lieu of a meeting) of
stockholders of the Company at or by which the Common Directors are to be
elected, the Designating Common Holders shall notify all of the Purchasers and
Stockholders in writing of the person designated for election as the Common
Director. In the absence of any such notification, it shall be presumed that the
incumbent Common Director, if any, has been redesignated for election as the
Common Director. The initial person designated for election as the Common
Director is Dr. Thomas G. Marr.

         (c)  So long as CSH is the beneficial owner of at least 40% of the
Shares purchased by CSH on the date hereof, CSH shall have the right to
designate a Nominee for election as one of the directors of the Company who
shall be elected solely by the holders of Common Stock (the "CSH Director")
pursuant to the Company's Certificate of Incorporation. At least 10 days prior
to any meeting (or written action in lieu of a meeting) of stockholders of the
Company at or by which the CSH Director is to be elected, CSH shall notify all
of the Purchasers and Stockholders in writing of the person designated for
election as the CSH Director. In the absence of any such notification, it shall
be presumed that the incumbent CSH Director, if any, has been redesignated for
election as the CSH Director. The initial person designated for election as the
CSH Director is [_______]. If CSH shall not be entitled to designate a CSH
Director pursuant to the terms hereof, the Designating Common Holders shall have
the right to nominate two directors (including the Common Director) who shall be
elected soley by the holders of Common Stock. For purposes of Section 3 below,
the CSH Director shall constitute a Common Director.

     3.  Election of Directors. At each meeting (or written action in lieu of a
meeting) of stockholders of the Company at or by which directors are to be
elected by the holders of the Series A Preferred, voting separately as a series,
each Purchaser shall vote (or execute a written consent with respect to) all of
its Shares to elect, as directors of the Company, the Nominees designated in the
manner provided in Section 2. At each
<PAGE>

meeting (or written action in lieu of a meeting) of stockholders of the Company
at or by which the Common Directors are to be elected, each Purchaser and
Stockholder shall vote (or execute a written consent with respect to) all of its
Shares entitled to vote to elect, as directors of the Company, the Common
Directors designated in the manner provided in Section 2; provided, that, until
an initial public offering of Common Stock (an "IPO"), such Common Directors
shall be a "Founder" or an employee thereof, as such term is defined in a
certain Founders' Agreements with the Company dated as of even date herewith.

     4.  Successor Directors. (a) If a Nominee shall cease to serve as a
director for any reason, the Nominating Purchaser which designated such Nominee
shall have the right to designate a successor Nominee and each of the other
Purchasers and Stockholders shall use its best efforts (including by voting (or
executing a written consent with respect to) all Shares which it is entitled to
vote) to ensure that such successor Nominee is duly elected as a director. If
the Common Director shall cease to serve as a director for any reason, the
Designating Common Holders may designate a successor Common Director and each of
the Purchasers and Stockholders shall use its best efforts (including by voting
(or executing a written consent with respect to) all Shares which it is entitled
to vote) to ensure that such successor Common Director is duly elected as a
director. If the CSH Director shall cease to serve as a director for any reason
and CSH then has the right to designate a Nominee for elections as a director
pursuant to Section 2(c), then CSH may designate a successor CSH Director and
each of the Purchasers and Stockholders shall use its best efforts (including by
voting (or executing a written consent with respect to) all Shares which it is
entitled to vote) to ensure that such successor CSH Director is duly elected as
a director.

         (b)  If a Nominating Purchaser notifies the other Purchasers that it
desires to remove its Nominee as a director, each of the other Purchasers shall
use its best efforts (including by voting (or executing a written consent with
respect to) all Shares which it is entitled to vote) to ensure that such Nominee
is duly removed as a director. If the Designating Common Holders notify the
Purchasers and Stockholders that they desire to remove the Common Director as a
director, each of the Purchasers and Stockholders shall use its best efforts
(including by voting (or executing a written consent with respect to) all Shares
which it is entitled to vote) to ensure that such Common Director is duly
removed as a director. If CSH notifies the Purchasers and Stockholders that it
desires to remove the CSH Director as a director and CSH then has the right to
designate a Nominee for elections as a director pursuant to Section 2(c), each
of the Purchasers and Stockholders shall use its best efforts (including by
voting (or executing a written consent with respect to) all Shares which it is
entitled to vote) to ensure that such CSH Director is dub removed as a director.

         (c)  If (i) a Nominating Purchaser notifies the Company that it desires
to remove its Nominee as a director and/or designate a successor Nominee, (ii)
the
<PAGE>

Designating Common Holders notify the Company that they desire to remove the
Common Director as a director and/or designate a successor Common Director, or
(iii) CSH notifies the Company that it desires to remove the CSH Director as a
director and/or designate a successor CSH Director and CSH then has the right to
designate a Nominee for elections as a director pursuant to Section 2(c), then
the Company shall, at the request of such Nominating Purchaser, Designating
Common Holders or CSH, as the case may be, use its best efforts to ensure that a
meeting of stockholders of the Company is promptly called for such purpose.

     5.  Term. This Agreement shall continue until the earlier of, and shall
automatically terminate and be of no further force or effect at (i) such time as
no shares of Series A Preferred remain outstanding or (ii) the tenth anniversary
of the date of this Agreement; provided that no such termination shall relieve a
party from liability for prior breaches hereof.

     6.  Specific Enforcement. Each party hereto expressly agrees that the
Purchasers, Stockholders and the Company will be irreparably damaged if this
Agreement is not specifically enforced. Upon a breach or threatened breach of
the terms, covenants and/or conditions of this Agreement by a Stockholder, a
Purchaser or the Company, the Purchasers, Stockholders and the Company, as the
case may be, shall, in addition to all other remedies, be entitled to a
temporary or permanent injunction, without showing any actual damage, and/or a
decree for specific performance, in accordance with the provisions hereof.

     7.  Legend. Each certificate evidencing Shares shall bear a legend
substantially as follows:

         "The shares represented by this certificate are subject to the
         terms and conditions of a certain Voting Agreement dated as of
         March ____, 1996, a copy of which the Company will furnish to
         the holder of this certificate upon request and without charge."

     8.  Amendment of Charter. The Purchasers shall not without the consent of
the holders of 75% of the shares of outstanding Common Stock, take any action to
amend the Bylaws or the Certificate of Incorporation of the Corporation to
increase the stated dividend rate of the Series A Preferred, accelerate the date
upon which such dividends shall accrue or increase the liquidation preference of
the Series A Preferred.

     9.  Notices. All notices or other communications given hereunder shall be
in writing and shall be deemed effective upon delivery at the address of the
party to be notified and shall be mailed by certified or registered mail, return
receipt requested, delivered by courier, telecopied, or sent by other facsimile
method (notices by telecopy or facsimile must be confirmed by next day courier
delivery to be effective), addressed to
<PAGE>

the address specified below such party's signature hereto or such other address
as such party may subsequently notify the other parties of in writing.

     10.  Entire Agreement and Amendments. This Agreement constitutes the entire
agreement of the parties with respect to the subject matter hereof and neither
this Agreement nor any provision hereof may be waived, modified, amended or
terminated except by a written agreement signed by the Company, Stockholders
owning at least two-thirds of the Shares of Common Stock owned by all
Stockholders and Purchasers owning at least two thirds of the shares of Common
Stock (assuming for such purpose that all shares of Preferred Stock have been
converted into Common Stock at such time) owned by all Purchasers, provided
however that neither Section 2(c) nor any other Section hereof necessary to
effectuate the intent of or to enforce Section 2(c) may be amended without the
consent of CSH.

     11.  Governing Law Successors and Assigns. This Agreement shall be governed
by the internal laws of the State of Delaware (without giving effect to its
conflict of law principles) and shall bind and inure to the benefit of the
heirs, personal representatives, executors, administrators, successors, assigns
and transferees of the parties. Without limiting the generality of the
foregoing, all covenants and agreements of the Stockholders and Purchasers shall
bind any and all subsequent holders of their Shares, and the Company agrees that
it shall not transfer on its records any such Shares unless (i) the transferor
Stockholder or Purchaser, as the case may be, shall have first delivered to the
Company and the Purchasers the written agreement of the transferee to be bound
by this Agreement to the same extent as if such transferee had originally been a
Stockholder or Purchaser hereunder, as the case may be, and (ii) the certificate
or certificates evidencing the Shares so transferred bear the legend specified
in Section 7.

     12.  Captions. Captions are for convenience only and are not deemed to be
part of this Agreement.

     13.  Counterpart. This Agreement may be executed in two or more
counterpart, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
<PAGE>

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year first above written

                                COMPANY

                                GENOMICA CORPORATION

                                By:  /s/ James L. Rathmann
                                   ------------------------------------
                                   James L. Rathmann
                                   President
                                   Address:  c/o
                                             Falcon Technology Partners, L.P.
                                             James L. Rathmann
                                             General Partner
                                             600 Dorset Road
                                             Devon, PA  19333

                                PURCHASERS:

                                FALCON TECHNOLOGY PARTNERS, L.P.

                                By:  /s/ James L. Rathmann
                                   ------------------------------------
                                   James L. Rathmann
                                   its General Partner

                                Address:  600 Dorset Road
                                          Devon, PA  19333

                                HARRIS & HARRIS GROUP, INC.

                                By:  /s/ David C. Johnson
                                   ------------------------------------
                                   David C. Johnson, Jr.
                                   Executive Vice President

                                Address:  One Rockefeller Plaza
                                          14 West 49th Street
                                          New York, New York 10020

                                  (Continued)
<PAGE>

                                STOCKHOLDERS:

                                COLD SPRING HARBOR LABORATORY

                                By:  /s/ John Maroney
                                   ------------------------------------
                                   John Maroney
                                   Assistant Administrative Director

                                HARRIS & HARRIS GROUP, INC.

                                By:  /s/
                                   ------------------------------------

                                /s/ Thomas Marr
                                ---------------------------------------
                                Dr. Thomas Marr

                                /s/ Donald Fisher
                                ---------------------------------------
                                Donald Fisher

                                /s/ Steven Cozza
                                ---------------------------------------
                                Steven Cozza

                                /s/ Jacqueline Salit
                                ---------------------------------------
                                Jacqueline Salit

                                /s/ John Maroney
                                ---------------------------------------
                                John Maroney

                                /s/ James L. Rathmann
                                ---------------------------------------
                                James L. Rathmann

                                  (Continued)
<PAGE>

                                /s/ Margaret C. Rathmann
                                ---------------------------------------
                                Margaret C. Rathmann

                                /s/ Laura Jean Rathmann
                                ---------------------------------------
                                Laura Jean Rathmann

                                /s/ Sally A. Rathmann
                                ---------------------------------------
                                Sally A. Rathmann

                                /s/ Richard G. Rathmann
                                ---------------------------------------
                                Richard G. Rathmann
<PAGE>

                         SUPPLEMENTAL VOTING AGREEMENT

     AGREEMENT dated as of February 28, 1997, by and among Genomica Corporation,
a Delaware corporation (the "Company"), the persons listed as Purchasers in
Schedule I to a certain Series A Convertible Preferred Stock Purchase Agreement
of the Company dated as of the date hereof (the "Purchase Agreement")
(collectively, the "Purchasers" and individually a "Purchaser") and the persons
listed as Prior Stockholders in the signature pages hereto (the Prior
Stockholders and the Purchasers are herein defined as the "Stockholders" and
individually, as a "Stockholder").

     WHEREAS, on the date hereof, the Purchasers are purchasing from the Company
shares of its Series A Preferred Stock (the "Series A Preferred") pursuant to
the terms of the Purchase Agreement, a copy of which is attached hereto as
Exhibit A; and

     WHEREAS, the Prior Stockholders are parties to that certain Voting
Agreement dated as of March 22, 1996 (the "Prior Voting Agreement"); and

     WHEREAS, the Purchasers and the Prior Stockholders wish to make certain
provisions for the voting of their Shares (as defined below); and

     WHEREAS, the Purchasers and the Prior Stockholders wish to make certain
provisions regarding the transfer of their Shares; and

     WHEREAS, the purchases by the Purchasers will benefit the Company; and

     WHEREAS, it is a condition to the obligations of the Purchasers under the
Purchase Agreement that this Agreement be executed by the parties hereto, and
the parties are willing to execute this Agreement and to be bound by the
provisions hereof;

     NOW, THEREFORE, in consideration of the premises, the agreements set forth
below, and the parties' desire to further the interests of the Company and its
present and future stockholders, the parties agree as follows:

     1.  Definition.  As used in this Agreement, the term "Shares" means all
shares of equity securities of the Company (i) now or hereafter owned (either
beneficially or of record) by a Prior Stockholder or a Purchaser, and (ii) which
a Prior Stockholder or a Purchaser does not own (either beneficially or of
record) but as to which it now or hereafter has the right to exercise voting
control.

     2.  Designation of Nominees.  Each of ARCH Venture Fund III, L.P. ("ARCH'')
and Boulder Ventures L.P. ("Boulder") (together, the "Nominating Purchasers" and
individually, a "Nominating Purchaser"), so long as they each own 400,000 shares
of Series A Preferred, shall have the right to designate a nominee (together,
the "Nominees" and individually, a "Nominee") for election as a director of the
Company. At least 10 days prior to any meeting (or written action

                                      -1-
<PAGE>

in lieu of a meeting) of stockholders of the Company at or by which directors
are to be elected by the holders of Series A Preferred voting separately as a
series, or by all stockholders of the Company, as applicable, each Nominating
Purchaser shall notify the other parties to this Agreement in writing of the
Nominee designated by such Nominating Purchaser for election as a director. In
the absence of any such notification, it shall be presumed that the Nominating
Purchaser's then incumbent Nominee has been redesignated as its Nominee. The
initial Nominees of ARCH and Boulder are Robert Nelson and Marvin Caruthers,
respectively. Each of the Prior Stockholders hereby agrees to designate one of
the Nominees as a "Nominee" pursuant to the Prior Voting Agreement so that the
Prior Stockholders shall together select two directors, one by Falcon Technology
Partners, L.P. and one by Harris and Harris Group, Inc., and the Nominating
Purchasers shall together select two directors, one by ARCH and one by Boulder.

     3.  Election of Directors.  At each meeting (or written action in lieu of a
meeting) of stockholders of the Company at or by which directors are to be
elected by the holders of the Series A Preferred voting separately as a series,
or by all stockholders of the Company, as applicable, each party hereto shall
vote (or execute a written consent with respect to) all of its Shares to elect,
as directors of the Company, the Nominees designated in the manner provided in
Section 2.

     4.  Successor Directors.  (a) If a Nominee shall cease to serve as a
director for any reason, the Nominating Purchaser which designated such Nominee
shall have the right to designate a successor Nominee and each of the other
parties hereto shall use its best efforts (including by voting (or executing a
written consent with respect to) all Shares which it is entitled to vote) to
ensure that such successor Nominee is duly elected as a director.

          (b) If a Nominating Purchaser notifies the other parties hereto that
it desires to remove its Nominee as a director, each of the other parties hereto
shall use its best efforts (including by voting (or executing a written consent
with respect to) all Shares which it is entitled to vote) to ensure that such
Nominee is duly removed as a director.

          (c) If a Nominating Purchaser notifies the Company that it desires to
remove its Nominee as a director and/or designate a successor Nominee, then the
Company shall, at the request of such Nominating Purchaser, use its best efforts
to ensure that a meeting of stockholders of the Company, or holders of the
Series A Preferred, as applicable, is promptly called for such purpose.

     5.  Right of First Refusal.

          (a) If at any time a Stockholder desires to sell all or any part of
its Shares pursuant to a bona fide offer from a third party other than an
affiliate of such Stockholder who agrees to be bound by the terms of this
Agreement (the "Proposed Buyer"), the Stockholder shall submit a written offer
(the "Offer") to sell such remaining Shares (the "Offered Shares") to the
remaining Stockholders (the "Other Stockholders") on terms and conditions,
including price, not less favorable to the Other Stockholders than those on
which the Stockholder proposes to sell the Offered Shares to the Proposed Buyer.
The Offer shall disclose the identity of the Proposed

                                      -2-
<PAGE>

Buyer, the Offered Shares proposed to be sold, the total number of Shares then
owned by the selling Stockholder, the terms and conditions, including price, of
the proposed sale, and any other material facts relating to the proposed sale.
The Offer shall further state that each Other Stockholders may acquire, in
accordance with the provisions of this Agreement, all or any portion of their
respective pro rata share (based upon the percentage of Shares held by such
Other Stockholder bears to the total of all Shares then held by all Other
Stockholders) of Offered Shares for the price and upon the other terms and
conditions, including deferred payment (if applicable), set forth therein.

          (b) If any Other Stockholder desires to purchase all or any part of
the Offered Shares, such Other Stockholder shall communicate in writing its
election to purchase to the selling Stockholder, which communication shall state
the number of Offered Shares such Other Stockholder desires to purchase and
shall be given to the selling Stockholder and each other Other Stockholder
within ten (10) business days of the date the Offer was made. Such communication
shall, when taken in conjunction with the Offer, be deemed to constitute a
valid, legally binding and enforceable agreement for the sale and purchase of
such Offered Shares. Sales of the Offered Shares to be sold to the Other
Stockholders pursuant to this Section 5 shall be made at the offices of the
Company on the 25th day following the date the Offer was made (or if such 25th
day is not a business day, then on the next succeeding business day). Such sales
shall be effected by the selling Stockholder's delivery to the Company of a
certificate or certificates evidencing the Offered Shares to be purchased by the
Other Stockholder, duly endorsed for transfer to the Other Stockholder, against
payment to the selling Stockholder of the purchase price therefor by the Other
Stockholder.

          (c) If less than all of the Offered shares are purchased by the Other
Stockholders, then no later than the second business day after the expiration of
the 10-day period referred to in Section 3(b) above, the Company shall offer in
writing (the "Second Notice") to each Other Stockholder which offered to
purchase Offered Shares, an option to purchase its Proportionate Share (as
defined below) of the Offered Securities which were not previously elected to be
purchased. Within five (5) days after the receipt by each of the Other
Stockholders of the Second Notice or attempted delivery during working hours to
his/her/its address shown on the books of the Company (such date is referred to
as the "Second Receipt Date"), each Other Stockholder who received a Second
Notice, by delivering a written notice to the Company (the "Second Reply"), may
elect to purchase, at the price and on the terms specified in the original
Offer, its Proportionate Share of the Offered Shares. As used herein,
"Proportionate Share" equals the total number of Offered Shares not previously
elected to be purchased multiplied by a fraction, the numerator of which is the
number of shares (on a fully-diluted basis) of Common Stock (assuming that all
shares of Series A Preferred had been converted) then held by such Other
Stockholders, and the denominator of which is the sum of all shares (on a fully-
diluted basis) of Common Stock (assuming that all shares of Series A Preferred
had been converted) then held by all Other Stockholders delivering a Second
Reply.

          (d) If the Other Stockholders do not purchase all of the Offered
Shares, the Offered Shares not so purchased may be sold by the selling
Stockholder at any time within six

                                      -3-
<PAGE>

months after the date the Offer was made, subject to the provisions of this
Agreement. Any such sale shall be to the Proposed Buyer, at not less than the
price and upon other terms and conditions, if any, not more favorable to the
Proposed Buyer than those specified in the Offer. Any Offered Shares not sold
within such six-month period shall continue to be subject to the requirements of
this Section 5.

     6.  Term.  This Agreement shall continue until the earlier of, and shall
automatically terminate and be of no further force or effect at (i) such time as
no Purchaser holds more than 400,000 shares of Series A Preferred or (ii) the
tenth anniversary of the date of this Agreement; provided that no such
termination shall relieve a party from liability for prior breaches hereof.

     7.  Specific Enforcement.  Each party hereto expressly agrees that the
Purchasers, the Prior Stockholders and the Company will be irreparably damaged
if this Agreement is not specifically enforced. Upon a breach or threatened
breach of the terms, covenants and/or conditions of this Agreement by a Prior
Stockholder, a Purchaser or the Company, the Purchasers, Prior Stockholders and
the Company, as the case may be, shall, in addition to all other remedies, be
entitled to a temporary or permanent injunction, without showing any actual
damage, and/or a decree for specific performance, in accordance with the
provisions hereof.

     8.  Legend. Each certificate evidencing Shares shall bear a legend
substantially as follows:

         "The shares represented by this certificate are subject to the terms
and conditions of a certain Supplemental Voting Agreement dated as of February
28, 1997, a copy of which the Company will furnish to the holder of this
certificate upon request and without charge."

     9.  Covenant of the Company.  The Company hereby agrees that it will not
issue any of its voting securities to any person, if after giving effect to such
issuance (a) the Stockholders would have insufficient voting power to effect the
transactions contemplated by Sections 3 and 4 hereof or (b) such purchasers do
not agree to the rights of the Stockholders herein contained.

     10.  Notices.  All notices or other communications given hereunder shall be
in writing and shall be deemed effective upon delivery at the address of the
party to be notified and shall be mailed by certified or registered mail, return
receipt requested, delivered by courier, telecopied, or sent by other facsimile
method (notices by telecopy or facsimile must be confirmed by next day courier
delivery to be effective), addressed to the address specified below such party's
signature hereto or such other address as such party may subsequently notify the
other parties of in writing.

     11.  Entire Agreement and Amendments.  This Agreement constitutes the
entire agreement of the parties with respect to the subject matter hereof and
neither this Agreement nor any provision hereof may be waived, modified, amended
or terminated except by a written agreement signed by the Company, Prior
Stockholders owning at least two-thirds of the Shares owned by all Prior
Stockholders and Purchasers owning at least two thirds of the Shares owned by
all Purchasers.

                                      -4-
<PAGE>

     12.  Governing Law; Successors and Assigns.  This Agreement shall be
governed by the internal laws of the State of Delaware (without giving effect to
its conflicts of law principles) and shall bind and inure to the benefit of the
heirs, personal representatives, executors, administrators, successors, assigns
and transferees of the parties. Without limiting the generality of the
foregoing, all covenants and agreements of the Prior Stockholders and Purchasers
shall bind any and all subsequent holders of their Shares, and the Company
agrees that it shall not transfer on its records any such Shares unless (i) the
transferor Prior Stockholder or Purchaser, as the case may be, shall have first
delivered to the Company the written agreement of the transferee to be bound by
this Agreement to the same extent as if such transferee had originally been a
Prior Stockholder or Purchaser hereunder, as the case may be, and (ii) the
certificate or certificates evidencing the Shares so transferred bear the legend
specified in Section 7.

     13.  Captions.  Captions are for convenience only and are not deemed to be
part of this Agreement.

     14.  Counterparts.  This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

                                      -5-
<PAGE>

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year first above written.

                                COMPANY:

                                GENOMICA CORPORATION

                                By:  /s/ James L. Rathmann
                                   ------------------------------------
                                   James L. Rathmann
                                   President
                                   Address:  600 Dorset Road
                                             Devon, PA 19333

                                PURCHASERS:

                                        ARCH VENTURE FUND III, L.P.

                                        By:  ARCH VENTURE PARTNERS,
                                        L.L.C., general partner

                                        By:  /s/
                                           -------------------------------------
                                                     Managing Director

                                        BOULDER VENTURES, L.P.

                                        By:  BV PARTNERS, L.L.C.

                                        By:  /s/
                                           -------------------------------------
                                           Partner

                                        PEGASUS TECHNOLOGY VENTURES, L.L.C.

                                        By:  /s/ Kenneth Collins
                                           -------------------------------------
                                           Kenneth Collins, Manager

                                        THE CARUTHERS FAMILY, L.L.C.

                                        By:  /s/ Marvin H. Caruthers
                                           -------------------------------------
                                           Marvin H. Caruthers, Manager

                                      -6-
<PAGE>

                                        PRIOR STOCKHOLDERS:

                                        FALCON TECHNOLOGY PARTNERS, L.P.

                                        By:  /s/ James L. Rathmann
                                           -------------------------------------
                                           James L. Rathmann
                                           its General Partner

                                        Address:  600 Dorset Road
                                                  Devon, PA 19333

                                        HARRIS & HARRIS GROUP, INC.

                                        By:  /s/ David C. Johnson, Jr.
                                           -------------------------------------
                                           David C. Johnson, Jr.
                                           Executive Vice President

                                        Address:  One Rockefeller Plaza
                                                  14 West 49th Street
                                                  New York, New York 10020

                                      -7-
<PAGE>

                  AMENDMENT TO SUPPLEMENTAL VOTING AGREEMENT

     This Amendment to Supplemental Voting Agreement (the "Amendment"), dated as
of June ___ , 1997, is by and among Genomica Corporation, a Delaware corporation
(the "Company"), the persons listed as Purchasers in Schedule I to that certain
Series A Convertible Preferred Stock Purchase Agreement (as amended, the
"Purchase Agreement") (individually a "Purchaser" and collectively
"Purchasers"), and the persons listed as Prior Stockholders in the signature
pages hereto.

                                   RECITALS

     A.  The Company and Purchasers have entered into that certain Amendment to
Series A Convertible Preferred Stock Purchase Agreement (the "Purchase Agreement
Amendment"), of even date herewith, pursuant to which the Purchase Agreement is
amended to make Frank Bonsal ("Bonsal") a party to the Purchase Agreement and
permit him to purchase certain shares of the Company's Series A Convertible
Preferred Stock.

     B.  As a condition to the execution and delivery of the Purchase Agreement
Amendment, the Company, Purchasers and the Prior Stockholders wish to have
Bonsal execute this Amendment so that he is bound by the terms and conditions of
the Supplemental Voting Agreement.

                                   AGREEMENT

     NOW, THEREFORE, for good and valuable consideration, the receipt and
adequacy of which is hereby acknowledged, the parties hereby amend the
Supplemental Voting Agreement as follows:

     1.  The signature page of the Supplemental Voting Agreement shall be
amended to add the following Purchaser:

         Frank Bonsal

     By execution of this Amendment, the Purchasers and the Prior Stockholders
agree that Bonsal shall become a party to the Supplemental Voting Agreement.
Except as expressly modified by this Amendment, the Supplemental Voting
Agreement shall remain in full force and effect without change.

     This Amendment may be executed in any number of counterparts, each of which
when executed and delivered shall be an original, but all of which together
shall constitute one and the same instrument.
<PAGE>

     IN WITNESS WHEREOF, the parties have executed this Amendment to be
effective as of the date first above written.

                                       GENOMICA CORPORATION, a Delaware
                                       corporation

                                       By: /s/ James Rathmann
                                          --------------------------------------
                                          James Rathmann, President

                                       FALCON TECHNOLOGY II PARTNERS, L.P.

                                       By:  FALCON TECHNOLOGY MANAGEMENT
                                       CORPORATION, general partner

                                       By: /s/ James Rathmann
                                          --------------------------------------
                                          James Rathmann, President

                                       ARCH VENTURE FUND III, L.P.

                                       By:  ARCH VENTURE PARTNERS, L.L.C.,
                                       general partner

                                       By: /s/
                                          --------------------------------------
                                          Managing Director

                                       BOULDER VENTURES, L.P.

                                       By:  BV PARTNERS, L.L.C., general partner

                                       By:  /s/ Kyle Lefkoff
                                          --------------------------------------
                                          Kyle Lefkoff, Manager

                                       PEGASUS TECHNOLOGY VENTURES, L.L.C.

                                       By:  /s/ Kenneth Collins
                                          --------------------------------------
                                          Kenneth Collins, Manager

                                       2
<PAGE>

                                          --------------------------------------
                                          Frank Bonsal

                                       THE CARUTHERS FAMILY, L.L.C.

                                       By: /s/ Marvin H. Caruthers
                                          --------------------------------------
                                          Marvin H. Caruthers, Manager

                                       PRIOR STOCKHOLDERS:

                                       FALCON TECHNOLOGY PARTNERS, L.P.

                                       By: /s/ James Rathmann
                                          --------------------------------------
                                          James Rathmann, General Partner

                                       HARRIS & HARRIS GROUP, INC.

                                       By: /s/ David C. Johnson, Jr.
                                          --------------------------------------
                                          David C. Johnson, Jr., Executive Vice
                                          President

                                       3
<PAGE>

               SECOND AMENDMENT TO SUPPLEMENTAL VOTING AGREEMENT

     This Second Amendment (the "Amendment"), dated as of October 6, 1997, to
the Supplemental Voting Agreement, dated as of February 28, 1997, as amended
(the "Supplemental Voting Agreement"), by and among Genomica Corporation, a
Delaware corporation (the "Company"), the persons listed as Purchasers in
Schedule I to the Series A Convertible Preferred Stock Purchase Agreement, dated
as of February 28, 1997, as amended (the "Purchase Agreement") (individually, a
"Purchaser" and collectively, the "Purchasers") and the Prior Stockholders
listed in the signature pages thereto (the "Prior Stockholders," and together
with the Purchasers, the "Stockholders"), is by and among the Company and the
Stockholders.

                                   RECITALS

     A.   The Company and the Purchasers have entered into that certain Second
Amendment to Series A Convertible Preferred Stock Purchase Agreement (the
"Purchase Agreement Amendment") of even date herewith, pursuant to which the
Purchase Agreement is being amended to make those parties listed on the Addendum
to Schedule I thereof (the "Investors") that are not already parties to the
Purchase Agreement parties to the Purchase Agreement (the "New Investors") and
to permit the Investors to purchase shares of the Company's Series A Convertible
Preferred Stock.

     B.   As a condition to the execution and delivery of the Purchase Agreement
Amendment, the Company and the Stockholders wish to (i) amend the Supplemental
Voting Agreement and (ii) have the New Investors execute this Amendment so that
they will be bound by the terms and conditions of the Supplemental Voting
Agreement.

                                   AGREEMENT

     Now, Therefore, for good and valuable consideration, the receipt and
adequacy of which is hereby acknowledged, the parties hereby amend the
Supplemental Voting Agreement as follows:

     1.   Section 2 of the Supplemental Voting Agreement is hereby amended and
restated to read in its entirety as follows:

     "2.  Designation of Nominees.  Each of Invesco Global Health Sciences Fund
          -----------------------
("Invesco"), ARCH Venture Fund III, L.P. ("ARCH") and Boulder Ventures L.P.
("Boulder") (together, the "Nominating Purchasers" and individually, a
"Nominating Purchaser") shall have the right to designate a nominee (together,
the "Nominees" and individually, a "Nominee") for election as a director of the
Company so long as the Nominating Purchaser in question owns 400,000 shares of
Series A Preferred. At least 10 days prior to any meeting (or written action in
lieu of a meeting) of stockholders of the Company at or by which directors are
to be elected by the holders of Series A Preferred voting separately as a
series, each Nominating Purchaser shall notify the other parties to this
Agreement in writing of the Nominee designated by such Nominating Purchaser for
election as a director. In the absence of any such notification, it shall be
presumed that the Nominating Purchaser's then incumbent Nominee has been
redesignated as

                                       1.
<PAGE>

its Nominee. The initial Nominees of Invesco, ARCH and Boulder are Ralph E.
Christoffersen, Robert Nelsen and Marvin Caruthers, respectively. Each of the
Prior Stockholders hereby agrees to designate one of the Nominees as a "Nominee"
pursuant to the Prior Voting Agreement and Harris & Harris Group, Inc.
("Harris") agrees that it will not have a right to nominate a director
individually, so that the Prior Stockholders shall select only one director (by
Falcon Technology Partners, L.P.), and the Nominating Purchasers shall together
select three directors, one by Invesco, one by ARCH and one by Boulder. Harris
and Invesco shall have the right to attend all meetings of the Board of
Directors in a nonvoting observer capacity, to receive notice of such meetings
at the same time and in the same manner notice is given to the members of the
Board of Directors and to receive the information provided by the Company to the
Board of Directors; provided, however, that the Company may require as a
condition precedent that the representatives of Harris and Invesco proposing to
attend any meeting of the Board of Directors and the representatives of Harris
and Invesco who will have access to any of the information provided by the
Company to the Board of Directors shall agree to hold in confidence and trust
and to act in a fiduciary manner with respect to all information so received
during such meetings or otherwise, and provided further that the failure to give
notice or to provide information to Harris or Invesco shall not affect or
nullify the actions taken by the Board of Directors."

     2.   Section 5 of the Supplemental Voting Agreement is hereby amended and
restated to read in its entirety as follows:

     "5.  Right of First Refusal.
          ----------------------

          (a)  If at any time a Stockholder desires to sell all or any part of
its Shares pursuant to a bona fide offer from a third party other than an
affiliate (which shall include a mutual fund with a common investment advisor as
a Stockholder) of such Stockholder who agrees to be bound by the terms of this
Agreement (the "Proposed Buyer"), the Stockholder shall submit a written offer
(the "Offer") to sell such Shares (the "Offered Shares") to the remaining
Stockholders (the "Other Stockholders") on terms and conditions, including
price, not less favorable to the Other Stockholders than those on which the
Stockholder proposes to sell the Offered Shares to the Proposed Buyer. The Offer
shall disclose the identity of the Proposed Buyer, the number of Offered Shares
proposed to be sold, the total number of Shares then owned by the selling
Stockholder, the terms and conditions, including price, of the proposed sale,
and any other material facts relating to the proposed sale. The Offer shall
further state that each Other Stockholder may acquire, in accordance with the
provisions of this Agreement, all or any portion of its pro rata share (based
upon the percentage of Shares held by such Other Stockholder bears to the total
of all Shares then held by all Other Stockholders) of Offered Shares for the
price and upon the other terms and conditions, including deferred payment (if
applicable), set forth therein.

          (b)  If any Other Stockholder desires to purchase all or any part of
the Offered Shares, such Other Stockholder shall communicate in writing its
election to purchase to the selling Stockholder, which communication shall state
the number of Offered Shares such Other Stockholder desires to purchase and
shall be given to the selling Stockholder and each Other Stockholder within ten
(10) business days of the date the Offer was received by such Other

                                       2.
<PAGE>

Stockholder. Such communication shall, when taken in conjunction with the Offer,
be deemed to constitute a valid, legally binding and enforceable agreement for
the sale and purchase of such Offered Shares. Sales of the Offered Shares to be
sold to the Other Stockholders pursuant to this Section 5 shall be made at the
offices of the Company on the 45th day following the date the Offer was made (or
if such 45th day is not a business day, then on the next succeeding business
day). Such sales shall be effected by the selling Stockholder's delivery to the
Company of a certificate or certificates evidencing the Offered Shares to be
purchased by the Other Stockholder, duly endorsed for transfer to the Other
Stockholder, against payment to the selling Stockholder of the purchase price
therefor by the Other Stockholder.

          (c)  If less than all of the Offered Shares are purchased by the Other
Stockholders, then no later than the second business day after the expiration of
the 10 business day period referred to in Section 3(b) above, the Company shall
offer in writing (the "Second Notice") to each Other Stockholder which offered
to purchase Offered Shares, an option to purchase its Proportionate Share (as
defined below) of the Offered Securities which were not previously elected to be
purchased. Within five (5) days after the receipt by each of the Other
Stockholders of the Second Notice or attempted delivery during working hours to
his/her/its address shown on the books of the Company (such date is referred to
as the "Second Receipt Date"), each Other Stockholder who received a Second
Notice, by delivering a written notice to the Company (the "Second Reply"), may
elect to purchase, at the price and on the terms specified in the original
Offer, up to its Proportionate Share of the Offered Shares. As used herein,
"Proportionate Share" equals the total number of Offered Shares not previously
elected to be purchased multiplied by a fraction, the numerator of which is the
number of shares (on a fully-diluted basis) of Common Stock (assuming that all
shares of Series A Preferred had been converted) then held by such Other
Stockholder, and the denominator of which is the sum of all shares (on a fully-
diluted basis) of Common Stock (assuming that all shares of Series A Preferred
had been converted) then held by all Other Stockholders delivering a Second
Reply.

          (d)  If the Other Stockholders do not purchase all of the Offered
Shares, the Offered Shares not so purchased may be sold by the selling
Stockholder at any time within three months after the date the Offer was made,
subject to the provisions of this Agreement. Any such sale shall be to the
Proposed Buyer, at not less than the price and upon other terms and conditions,
if any, not more favorable to the Proposed Buyer than those specified in the
Offer. Any Offered Shares not sold within such three-month period shall continue
to be subject to the requirements of this Section 5."

     3.   Section 6 of the Supplemental Voting Agreement is hereby amended and
restated to read in its entirety as follows:

     "6.  Term. This Agreement shall continue until the earlier of, and shall
          ----
automatically terminate and be of no further force or effect at (i) such time as
no Purchaser holds more than 400,000 shares of Series A Preferred; (ii) the
tenth anniversary of the date of this Agreement; or (iii) the completion of a
firmly underwritten public offering of the Company's Common Stock at a price of
at least $2.50 per share and which raises at least $5,000,000 of gross proceeds
to the

                                       3.
<PAGE>

Company; provided that no such termination shall relieve a party from liability
for prior breaches hereof."

     4.   The signature pages to the Supplemental Voting Agreement shall be
amended to add the following New Investor:

               Invesco Global Health Sciences Fund

     By execution of this Amendment, the Stockholders and the New Investor agree
that the New Investor shall become a party to the Supplemental Voting Agreement.
Except as expressly modified by this Amendment, the Supplemental Voting
Agreement shall remain in full force and effect without change.

     This Amendment may be executed in any number of counterparts, each of which
when executed and delivered shall be an original, but all of which together
shall constitute one and same instrument.

                 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       4.
<PAGE>

     In Witness Whereof, the parties have executed this Amendment to be
effective as of the date first above written.

                                   Genomica Corporation, a Delaware corporation

                                   By: /s/ Thomas G. Marr,
                                       ___________________________________
                                       Dr. Thomas G. Marr, President

                                   Stockholders:

                                   Falcon Technology II Partners, L.P.

                                   By: Falcon Technology Management Corporation,
                                       general partner

                                   By: /s/ James Rathmann
                                       ___________________________________
                                       James Rathmann, President

                                   Arch Venture Fund III, L.P.

                                   By: Arch Venture Partners, L.L.C., general
                                       partner

                                   By: /s/ Robert Nelsen
                                       ___________________________________
                                       Managing Director

                                   Boulder Ventures, L.P.

                                   By: BV Partners, L.L.C., general partner

                                   By: /s/ Kyle Lefkoff
                                       ___________________________________
                                       Kyle Lefkoff, Manager

                                   Pegasus Technology Ventures, L.L.C.

                                   By: /s/ Kenneth Collins
                                       ___________________________________
                                       Kenneth Collins, Manager

                  AMENDMENT TO SUPPLEMENTAL VOTING AGREEMENT
<PAGE>

                                        The Caruthers Family, L.L.C.

                                        By: /s/ Marvin H. Caruthers
                                            _________________________________
                                            Marvin H. Caruthers, Manager

                                        Frank Bonsal

                                        _____________________________________
                                        Frank Bonsal

                                        Falcon Technology Partners, L.P.

                                        By: /s/ James L. Rathmann
                                            _________________________________
                                            James L. Rathmann, General Partner

                                        Harris & Harris Group, Inc.

                                        By: /s/ David C. Johnson, Jr.
                                            _________________________________
                                            David C. Johnson, Jr.,
                                            Executive Vice President

                                        New Investor:

                                        Invesco Global Health Sciences Fund

                                        By: /s/ Ronald L. Grooms
                                            _________________________________

                                        Name:   Treasurer
                                              _______________________________

                                        Title:  Ronald L. Grooms
                                               ______________________________

                                        New Investor:

                                        Invesco Global Health Sciences Fund

                                        By: /s/ Glen A. Payne
                                            _________________________________

                                        Name:   Glen A. Payne
                                              _______________________________

                                        Title:  Secretary
                                               ______________________________

                  AMENDMENT TO SUPPLEMENTAL VOTING AGREEMENT
<PAGE>

               THIRD AMENDMENT TO SUPPLEMENTAL VOTING AGREEMENT

     This Third Amendment (the "Amendment"), dated as of October 20, 1997, to
the Supplemental Voting Agreement, dated as of February 28, 1997, as amended
(the "Supplemental Voting Agreement"), by and among Genomica Corporation, a
Delaware corporation (the "Company"), the persons listed as Purchasers in
Schedule I to the Series A Convertible Preferred Stock Purchase Agreement, dated
as of February 28, 1997, as amended (the "Purchase Agreement") (individually, a
"Purchaser" and collectively, the "Purchasers") and the Prior Stockholders
listed in the signature pages thereto (the "Prior Stockholders," and together
with the Purchasers, the "Stockholders"), is by and among the Company and the
Stockholders.

                                   RECITALS

     A.   The Purchase Agreement is being amended to make the party listed on
the Addendum to Schedule I thereof, which is attached hereto (the "New
Investor"), a party to the Purchase Agreement and to permit the New Investor to
purchase shares of the Company's Series A Convertible Preferred Stock.

     B.   In connection with the purchase of shares of the Company's Series A
Convertible Preferred Stock by the New Investor, the Company and the
Stockholders wish to have the New Investor execute this Amendment so that the
New Investor will be bound by the terms and conditions of the Supplemental
Voting Agreement.

                                   AGREEMENT

     Now, Therefore, for good and valuable consideration, the receipt and
adequacy of which is hereby acknowledged, the parties hereby amend the
Supplemental Voting Agreement as follows:

     The signature pages to the Supplemental Voting Agreement shall be amended
to add the following New Investor:

               David B. Musket SEP IRA

     By execution of this Amendment, the Stockholders and the New Investor agree
that the New Investor shall become a party to the Supplemental Voting Agreement.
Except as expressly modified by this Amendment, the Supplemental Voting
Agreement shall remain in full force and effect without change.

     This Amendment may be executed in any number of counterparts, each of which
when executed and delivered shall be an original, but all of which together
shall constitute one and same instrument.

                 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                      1.
<PAGE>

     In Witness Whereof, the parties have executed this Amendment to be
effective as of the date first above written.

                                   Genomica Corporation, a Delaware corporation

                                   By: /s/ Thomas G. Marr
                                       ----------------------------------------
                                       Dr. Thomas G. Marr, President

                                   Stockholders:

                                   Falcon Technology II Partners, L.P.

                                   By: Falcon Technology Management Corporation,
                                       general partner

                                   By: /s/ James Rathmann
                                       ----------------------------------------
                                       James Rathmann, President

                                   Arch Venture Fund III, L.P.

                                   By: Arch Venture Partners, L.L.C., general
                                       partner

                                   By: /s/ Robert Nelsen
                                       ----------------------------------------
                                       Managing Director

                                   Boulder Ventures, L.P.

                                   By: BV Partners, L.L.C., general partner

                                   By: ________________________________________
                                       Kyle Lefkoff, Manager

                                   Pegasus Technology Ventures, L.L.C.

                                   By: /s/ Kenneth Collins
                                       ----------------------------------------
                                       Kenneth Collins, Manager

               THIRD AMENDMENT TO SUPPLEMENTAL VOTING AGREEMENT

<PAGE>

                                   The Caruthers Family, L.L.C.

                                   By: ________________________________________
                                       Marvin H. Caruthers, Manager

                                   Frank Bonsal

                                   ____________________________________________
                                   Frank Bonsal

                                   Falcon Technology Partners, L.P.

                                   By: /s/ James L. Rathmann
                                       ----------------------------------------
                                       James L. Rathmann, General Partner

                                   Harris & Harris Group, Inc.

                                   By: /s/ David C. Johnson, Jr.,
                                       ----------------------------------------
                                       David C. Johnson, Jr.,
                                       Executive Vice President

                                   Invesco Global Health Sciences Fund

                                   By: /s/ Glen A. Payne
                                       ----------------------------------------

                                   Name:   Glen A. Payne
                                         --------------------------------------

                                   Title:  Secretary
                                          -------------------------------------

                                   New Investor:

                                   David B. Musket SEP IRA

                                   By: /s/ David B. Musket
                                       ----------------------------------------

                                   Name:   David B. Musket
                                         --------------------------------------

                                   Title:
                                          -------------------------------------

                  AMENDMENT TO SUPPLEMENTAL VOTING AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}]]